Bioaktie 0,06 USD noch! - 500 Beiträge pro Seite

[can2]

WKN: 765803 Immune Response (OTC/BB nun!)ca.66 Mio Shares. Siehe News:






Könnte eine neue Biocurex-Rakete werden? Remember:



Börse
NASDAQ OTC BB

Aktuell
0,06 USD

Zeit
30.01.06 17:16

Diff. Vortag
+20,00 %

Tages-Vol.
65.336,86

Gehandelte Stück
1,2 Mio.

Geld
0,05

Brief
0,065

Zeit
30.01.06 17:16

Spread
23,077%

Geld Stk.
5.000

Brief Stk.
--

[Datteljongleur]

[posting]19.961.485 von can2 am 30.01.06 17:39:06[/posting]Keine Fakten???
Was macht die Firma usw. ?

[oski]

0.061-0.062 plus 22%
der chart sieht einladend aus

[oski]

0.065-0.067 plus 34%

[oski]

0.074-0.075 plus 50%

[oski]

SK 0.081 plus 62%

[meikelgu]

Frage:
Wird am 3.2.06 ein Delisting erfolgen???
Da war doch diese 60-Tage-Frist im November

[meikelgu]

Kann mir wer sagen, ob ein Delisting an der nas droht??
Und wenn es eines gibt-was hat das für Folgen??
Ist für mich eine der entscheidenen Fragen.

[oski]

[posting]19.966.597 von meikelgu am 30.01.06 22:29:09[/posting]bis jetzt nichts neues
die sind immer noch an der OTC dotiert

[meikelgu]

Stimmt auch wieder.
Letzte nas Notierung ist 23.11.05
Mh-vielleicht baue ich morgen eine position auf.
aber wohl besser in usa.
bin mal gespannt

gute n8

[oski]

ja aber sei vorsichtig kann wieder schnell fallen

[oski]

--------------------------------------------------------------------------------


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): January 24, 2006


The Immune Response Corporation
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware 000-18006 33-0255679
_____________________
(State or other jurisdiction _____________
(Commission ______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)

5931 Darwin Court, Carlsbad, California 92008
_________________________________
(Address of principal executive offices) ___________
(Zip Code)


Registrant’s telephone number, including area code: [phone]

Not Applicable
______________________________________________
Former name or former address, if changed since last report



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




--------------------------------------------------------------------------------

Top of the Form
Item 3.02 Unregistered Sales of Equity Securities.

Pursuant to our Standby Equity Distribution Agreement ("SEDA") dated July 15, 2005, we sold 7,936,508 shares of common stock to Cornell Capital Partners, LP ("Cornell Capital") on January 24, 2006. In accordance with the SEDA, the number of shares was calculated as $250,000 divided by $0.0315. We selected $250,000 as the gross advance for this particular SEDA transaction. The $0.0315 price per share was calculated, under the SEDA, by multiplying the lowest daily volume weighted average price (as quoted by Bloomberg L.P.) in the five-day trading period from January 17, 2006 to January 23, 2006 by 97%. From the indicated $250,000 gross advance, we actually received cash proceeds of $237,000 net of a 5% retainage fee and a $500 structuring fee.

We have stated in a SEC registration statement that the 3% discount and the 5% retainage fee constitute underwriting discounts, as does the $515,000 commitment fee (paid in the form of 725,353 shares of our common stock) which we paid to Cornell Capital in respect of the entire $15,000,000 SEDA commitment on July 15, 2005. The 7,936,508 shares were issued to Cornell Capital pursuant to the Securities Act Section 4(2) registration exemption.









--------------------------------------------------------------------------------

Top of the Form
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


The Immune Response Corporation

January 30, 2006 By: /s/ Michael K. Green


--------------------------------------------------------------------------------

Name: Michael K. Green
Title: Chief Operating Officer & Chief Financial Officer

[can2]

Kopie:
WKN: 2020545 (66 Mio Shares)
hi,
ich habe ein gutes gefühl langfristig bei IMNR, auch wenn das delisting nun nicht zu vermeiden war. normalerweise bin ich mittlerweile sehr vorsichtig bei OTC aktien, denke aber in diesem fall an keine abzockergeschichte mit z.B aktienverwässerung etc wie sonst so oft an der otc...ein garant ist das natürlich nicht, aber die fakten haben mich überzeugt...das unternehmen hat mehrmals versucht, daß delisting zu umgehen und haben sogar die letzte chance einer anhörung vor der NASDAQ wahrgenommen.

des weiteren haben die keine diversen namensänderung bzw symbolwechsel gehabt, wie so viele buden an der otc. das unternehmen wird meiner meinung wieder versuchen an die NASDAQ zu kommen. wer die ganzen news verfolgt hat, hat sicherlich auch die geschichte mit den warrants mitbekommen. ich glaube da war doch dieser Dr.XXX, der gute 10% der Aktien einsacken will und sein pulver investiert.(kaufoption bei guten 30cent?)
zudem nicht zu vergessen, stand der dinge : medikamente ist in phase I-II! Also für mich persönlich ist das eine heiße spekulation, wer risiko liebt, kann hier eventuell mit wenig einsatz einen treffer landen. (Remember:Biocurex)66 mio aktien lassen viel luft nach oben, wenn alles gut geht!?

The Immune Response Corporation Listed on OTC Bulletin Board
The Immune Response Corporation (OTCBB:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), today announced that it has been listed on the OTC Bulletin Board effective at the open of business on Monday, December 19, 2005.

About The Immune Response Corporation

The Immune Response Corporation (OTCBB:IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and MS. The Company`s HIV products are based on its patented whole inactivated virus technology, co-invented by Company founder Dr. Jonas Salk to stimulate HIV immune responses. REMUNE(R), currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a Toll-like receptor (TLR) agonist-based adjuvant and is currently in Phase I/II clinical trials in Canada, Italy and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVax(TM), which is currently in Phase II clinical trials and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com.

About the OTC Bulletin Board (OTCBB)

The OTC Bulletin Board (OTCBB) is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in Over-The-Counter equity securities. OTCBB securities include national, regional, and foreign equity issues, warrants, units, ADRs, and Direct Participation Programs (DPPs). More information is available at http://www.otcbb.com.

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials, and any transition issues related to the hiring of Joseph F. O`Neill as Chief Executive Officer. A more extensive set of risks is set forth in The Immune Response Corporation`s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.

[can2]

hammer volumen heute, bin mal gespannt, was die nächsten tage noch kommt?

Börse
NASDAQ OTC BB

Aktuell
0,106 USD

Zeit
31.01.06 17:48

Diff. Vortag
+30,86 %

Tages-Vol.
402.733,41

Gehandelte Stück
4 Mio.

Geld
0,106

Brief
0,11

[oski]

0.105 plus 30%

[can2]

@oski
hab ein kleines paket im depot, wenn es der burner wird, bin ich halt klein dabei!

[meikelgu]

1 Mio-Stücke sind da gestern noch in einer Order umgegangen.
Heftig.
Bin mal gespannt, wie es weitergeht hier.

[meikelgu]

Hat noch wer eine Meinung zu dieser Aktie?
Wie weit sind die Medikamente in der Pipeline
und ist man bestrebt, wieder in die NAS zu kommen?

[meikelgu]

Geht ja wieder heftig hoch bei massivne Umsätzen

[oski]

Data Indicate That Whole-Inactivated HIV-1 Immunogen Induces HIV-Specific Immune Responses in HIV-Infected, HAART-Naive Patients; Final Data from IMNR.OB`s Italian Study Presented in Poster at CROI Annual Meeting
Feb 10, 2006 7:00:00 AM
Copyright Business Wire 2006
CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 10, 2006--

The Immune Response Corporation (OTCBB:IMNR) announced today that the final results from a Phase II clinical study indicate that the Company`s whole-inactivated HIV-1 immunogen induces HIV-specific immune responses in HIV-infected, antiretroviral drug-naive patients. Specifically, this original formulation product showed potential to stimulate key immunologic parameters and to stabilize the loss of CD4+ cells, which could help prolong the time before these patients need to initiate antiretroviral therapy. The poster was presented at this week`s 13th Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

"CD4+ counts may be an especially important marker of disease progression and we plan to build on this data with our most potent clinical candidate, IR103," noted Joseph O`Neill, M.D., President and Chief Executive Officer of The Immune Response Corporation. "We have two ongoing clinical studies that will investigate IR103 in the drug-naive patient population. We will be expanding them and look forward to reporting the findings."

The analysis included data from 49 patients that completed the study, and showed that median absolute CD4+ cell counts remained stable through week 28 in the patients that received three injections of the HIV-1 immunogen but declined in both the IFA and saline groups. The HIV-1 immunogen`s effect on immune reconstitution was evidenced by an augmented production of factors known to reduce HIV replication, such as beta chemokines and alpha defensin. These data suggest a possible mode of action via boosting the body`s own defense against HIV, which could play a role in delaying the initiation of antiretroviral therapy.

The multi-center, single-blind, randomized study followed a total of 51 patients over 28 weeks following treatment with the Company`s patented HIV-1 immunogen, IFA or saline. Patients were antiretroviral-therapy naive and had HIV RNA levels between 10,000 and 40,000 copies/mL and CD4+ counts between 400 and 800 cells/uL at study entry. Patients received three injections of the HIV-1 immunogen (n=19), IFA (n=10), or saline (n=11) at weeks 0, 12, and 24. A fourth group received only a single injection of the HIV-1 immunogen at week 0 (n = 11). Although minor adverse events were reported, no treatment-limiting toxicities have been recorded to date.

This trial was intended to explore the potential utility of the HIV-1 immunogen and was not designed to have enough statistical power to be used for regulatory approval. The Company is planning a clinical program that would use the data from this and other trials to design IR103 trials in the near future. The HIV-1 immunogen and IR103 are not approved by any regulatory agencies in any country at this time.

About IR103

More than 25 million people have died since human immunodeficiency virus (HIV) was first recognized in 1981 (source: UNAIDS, December 2005), and the new infection rate continues to grow at an alarming rate. Despite medical advances, the worldwide pandemic continues to claim more than 3.1 million lives each year (source: UNAIDS, December 2005). Additional safe and effective treatments are desperately needed.

IR103 is a second-generation HIV immunotherapy based on the Company`s patented whole-inactivated virus technology, which was co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of the Company`s HIV-1 immunogen (REMUNE(R)), the Company`s first generation HIV product candidate. Preclinical research and recent clinical data show that IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. This product differs from currently available antiretroviral drug therapies since it is designed to stimulate an HIV-infected individual`s immune system to fight the virus.

The Company recently completed the first part of a 49-patient Phase I/II five-arm, randomized, single-blind, controlled, multi-center clinical study of safety and bioactivity of IR103 in HIV patients on HAART (highly active antiretroviral therapy) at sites in the United Kingdom and Canada, and plans to report new data as they become available later this year. Preliminary results of this trial, reported last year, indicate that IR103 is safe, induces HIV-specific immune responses and greatly enhances IFN-gamma and RANTES mRNA. IFN-gamma and RANTES are considered immune system markers that give an estimate of the robustness of the immune response generated by IR103 in patients.

The second part of this study, along with another similar study in Italy, will investigate IR103 as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. These studies, which the Company plans to expand, will ultimately enroll over 200 drug naive patients. Along with tracking safety and measuring HIV-specific immune responses, these studies will assess IR103`s ability to affect patients` CD4+ counts. CD4+ count is a critical marker of HIV disease progression that is used, along with viral load, to determine when a patient should begin antiretroviral therapy. The Company believes an immune-based therapy that could stabilize CD4+ counts could be used to delay initiation of antiretroviral therapy and serve as an important advance in the treatment of HIV. Final data from a drug-naive patient Phase II Italian study of REMUNE(R) showed that median absolute CD4+ cell counts of patients that received three injections of the Company`s first generation immunotherapy remained stable through week 28, while declining in patients in the placebo groups. The Company believes that the increased potency of IR103 could translate to a more durable and pronounced effect on CD4+ counts.

[oski]

yeahhhh
0.136 plus 80%

[meikelgu]

Danke für den guten Tip !

[oski]

[posting]20.139.230 von meikelgu am 10.02.06 17:31:55[/posting]wenn IMNR eines tages da mittel gegen HIV präsentiert
dann gute nacht

[oski]

mein schlusskurs tipp 0.2

[oski]

11:23:34 1,200 0.1350
11:23:34 1,200 0.1320
11:23:25 5,000 0.1320
11:23:25 5,000 0.1350
11:21:22 1,975 0.1380
11:19:48 175,000 0.1370
11:19:42 5,000 0.1310
11:18:05 20,000 0.1390
11:17:07 25,000 0.1310
11:12:34 25,000 0.1380
11:11:20 1,400 0.1380
11:09:46 20,000 0.1380
11:09:46 20,000 0.1360

[meikelgu]

Oski
ich würde es dir gönnen mit 0,2.
Mein Tip liegt bei 0,12
Wunsch wäre 0,09 :-)
Bin schon raus; will mich aber nicht beklagen. Tolle Sache gewesen :-)

[can2]

da steckt mehr hinter, das volumen ist auffällig!

Börse
NASDAQ OTC BB

Aktuell
0,13 USD

Zeit
10.02.06 19:12

Diff. Vortag
+68,83 %

Tages-Vol.
1,37 Mio.

Gehandelte Stück
11 Mio.

Geld
0,13

Brief
0,134

Zeit
10.02.06 18:52

Spread
2,985%

Geld Stk.
5.000

Brief Stk.
5.000

[hanspeterli]

Hi,
hier was zur Info

http://translate.google.com/translate?hl=de&sl=en&u=http://w…

[hanspeterli]

nachricht von heute

Daten zeigen, daß Vollständig-Inaktiviertes Hiv-1 Immunogen HIV-Spezifische immune Antworten verursacht, in HIV-Angesteckt, Patienten HAART-Naïve
Abschließende Daten von der italienischen Studie IMNR.OB`s stellten sich im Plakat bei der jährlichen Sitzung CROI

Carlsbad, Ca - Februar 10, 2006 - die immunes Wartekorporation (OTCBB:IMNR.OB) verkündete heute, daß die abschließenden Resultate von einer klinischen Studie der Phase II anzeigen, daß das vollständig-inaktivierte immunogen Hiv-1 der Firma HIV-spezifische immune Antworten bei den HIV-angesteckten verursacht, antiretroviral Droge-naïvepatienten. Spezifisch zeigte dieses ursprüngliche Formulierungprodukt Potential, immunologische Schlüsselparameter anzuregen und den Verlust der CD4+-Zellen zu stabilisieren, die helfen konnten, die Zeit auszudehnen, bevor diese Patienten antiretroviral Therapie einleiten müssen. Das Plakat wurde bei der 13. Konferenz dieser Woche auf Infektion Retroviruses und Opportunistic (CROI) in Denver dargestellt.

"CD4+-Zählimpulse können eine besonders wichtige Markierung der Krankheitweiterentwicklung sein und wir planen, auf diesen Daten mit unserem stärksten klinischen Anwärter, IR103," notierten Joseph O`Neill, M.D., Präsidenten und Generaldirektor der immunes Wartekorporation zu errichten. "wir haben zwei fortwährende klinische Studien, die IR103 in der Droge-naiven geduldigen Bevölkerung nachforschen. Wir werden erweitern sie und zum Berichten über die Entdeckungen vorwärts zu schauen.",

Die Analyse umfaßte Daten von 49 Patienten, die die Studie durchführten, und zeigte, daß mittlere Zellenzählimpulse des Absoluten CD4+ durch Woche 28 bei den Patienten beständig blieben, die drei Einspritzungen des immunogen Hiv-1 empfingen, aber im IFA und in den salzigen Gruppen sanken. Der Effekt der immunogens Hiv-1 auf immune Wiederherstellung wurde durch eine vergrößerte Produktion der Faktoren bewiesen, die bekannt sind, um HIV-Reproduktion, wie Betachemokines und Alphadefensin zu verringern. Diese Daten schlagen einen möglichen Modus der Tätigkeit über das Aufladen eigener Verteidigung des Körpers gegen HIV vor, der eine Rolle in delaying spielen könnte die Einführung der antiretroviral Therapie.

Der Multi-center, einzeln-blinde, randomisierte Studie folgte einer Gesamtmenge von 51 Patienten über 28 Wochen, die Behandlung mit der patentierten dem immunogen Hiv-1, IFA oder salzigem Firma folgen. Patienten waren die naïve Antiretroviraltherapie und hatten HIV-RNS-Niveaus zwischen 10.000 und 40.000 copies/mL und CD4+-Zählimpulsen zwischen 400 und 800 cells/µL an der Studieneintragung. Patienten empfingen drei Einspritzungen des immunogen Hiv-1 (n=19), des IFA (n=10) oder des salzigen (n=11) an Wochen 0, 12 und 24. Eine 4. Gruppe empfing nur eine einzelne Einspritzung des immunogen Hiv-1 an Woche 0 (n = 11). Obgleich nachteilige Fälle des Minderjährigen berichtet wurden, ist keine Behandlung-Begrenzungsgiftigkeit bis jetzt notiert worden.

Dieser Versuch sollte das mögliche Gebrauchs des immunogen Hiv-1 erforschen und wurde nicht entworfen, um genügend statistische Energie zu haben, für Genehmigung durch die zuständige Aufsichtsbehörde verwendet zu werden. Die Firma plant ein klinisches Programm, das die Daten von diesem und von anderen Versuchen verwenden würde, um Versuche IR103 in naher Zukunft zu entwerfen. Das immunogen Hiv-1 und die IR103 werden nicht durch irgendwelche Aufsichtsbehörden in irgendeinem Land diesmal genehmigt.

Über IR103

Mehr als 25 Million Leute sind gestorben, seit menschliches Immunodeficiencyvirus (HIV) zuerst 1981 erkannt wurde (Quelle: UNAIDS, Dezember 2005) und die neue Infektionsrate fährt fort, mit einer alarming Rate zu wachsen. Trotz der medizinischen Fortschritte fährt das weltweite pandemic fort, mehr als 3,1 Million Leben jedes Jahr zu behaupten (Quelle: UNAIDS, Dezember 2005). Zusätzliche sichere und wirkungsvolle Behandlungen werden hoffnungslos benötigt.

IR103 ist ein der zweiten GenerationcHiv-Immunotherapy, der auf der patentierten vollständig-inaktivierten Virustechnologie der Firma basiert, die vom Dr. Jonas Salk Co-erfunden wurde und angezeigt, um in den umfangreichen klinischen Studien des Hiv-1immungen der Firma (REMUNE®) sicher und immunisierend zu sein, der HIV-Produktanwärter des ersten Erzeugung der Firma. Forschung Preclinical und neue klinische Daten zeigen, daß IR103 eine stärkere Formulierung ist, die sein vollständig-inaktiviertes Antigen mit einem Chemiefasergewebe Abgabe-wie Agonist des Empfängers (Tlr-9) kombiniert, um erhöhte HIV-spezifische immune Antworten zu verursachen. Dieses Produkt unterscheidet sich von den zur Zeit verfügbaren antiretroviral Drogetherapien, da es entworfen wird, um das immune System einer HIV-angesteckten Einzelperson anzuregen, das Virus zu kämpfen.

Die Firma führte vor kurzem das erste Teil eines 49-patient Fünfarmes der Phase I/II, randomisierten, einzeln-blinden, kontrollierten, des Multi-center klinischen der Studie der Sicherheit und der Bioaktivität von IR103 bei HIV-Patienten auf HAART (in hohem Grade aktive antiretroviral Therapie) an den Aufstellungsorten im vereinigten Königreich und im Kanada und der Pläne, um über neue Daten zu berichten durch, während sie dieses Jahr vorhandenes späteres werden. Die einleitenden Resultate dieses Versuches, letztes Jahr berichtet, zeigen an, daß IR103 sicher ist, verursachen HIV-spezifische immune Antworten und erhöhen groß IFN-Gamma und RANTES-mRNA. IFN-Gamma und RANTES gelten als Markierungen des immunen Systems, die eine Schätzung der Robustheit der immunen Antwort geben, die von IR103 bei Patienten erzeugt wird.

Das zweite Teil dieser Studie, zusammen mit einer anderen ähnlichen Studie in Italien, forscht IR103 als first-line Behandlung für die Droge-naïve HIV-angesteckten Einzelpersonen nicht schon geeignet für antiretroviral Therapie entsprechend gegenwärtigen medizinischen Richtlinien nach. Diese Studien, die die Firma plant, zu erweitern, schreiben schließlich über 200 naïve Patienten der Droge ein. Zusammen mit aufspürensicherheit und messenden HIV-spezifischen immunen Antworten setzen diese Studien IR103`s-Fähigkeit fest, CD4+-Zählimpulse der Patienten zu beeinflussen. CD4+-Zählimpuls ist eine kritische Markierung der HIV-Krankheitweiterentwicklung, die, zusammen mit Virenlast verwendet wird, um festzustellen wann ein Patient antiretroviral Therapie anfangen sollte. Die Firma glaubt, daß eine immun-gegründete Therapie, die stabilisieren könnte, CD4+-Zählimpulse an gewöhntSEIN könnte verzögert Einführung der antiretroviral Therapie und Serve als wichtiger Fortschritt in der Behandlung von Daten HIV. Final von einer italienischen Studie der Phase II der Droge-naïve geduldiges von REMUNE® zeigte, daß mittlere Zellenzählimpulse des Absoluten CD4+ Patienten, die empfingen, drei Einspritzungen des Immunotherapy des ersten Erzeugung der Firma durch Woche 28 beständig blieben, während das Sinken bei Patienten im Placebo gruppiert. Die Firma glaubt, daß die erhöhte Kraft von IR103 zu einem haltbareren und pronounced Effekt auf CD4+-Zählimpulse übersetzen könnte.

Über Die Immunes WartecKorporation

Die Immunes WartecKorporation (OTCBB: IMNR.OB) ist eine Immun-pharmazeutische Firma, die auf sich entwickelnde Produkte gerichtet wird, um die autoimmunen und ansteckenden Krankheiten zu behandeln. Die immun-gegründeten therapeutischen Produktanwärter der Firma Leitung sind NeuroVax™ für die Behandlung der mehrfachen Sklerose (MS) und IR103 für die Behandlung der HIV-Infektion. Beide dieser Therapien sind in der klinischen Entwicklung der Phase II und werden entworfen, Krankheitserreger-spezifische immune Antworten angestrebtes Verlangsamen oder Anhalten anzuregen der Rate der Krankheitweiterentwicklung.

NeuroVax™, das auf der des T-Zellenempfängers der Firma patentierten Peptidtechnologie (TCR) basiert, hat dargestellt, daß möglicher klinischer Wert in der Behandlung der Zurückfallenformen von MS NeuroVax™ gezeigt worden ist, um starke vermittelte Immunität der Krankheit spezifische Zelle bei fast allen Patienten anzuregen, die behandelt werden und, zu arbeiten scheint, indem man Niveaus der Zellen FOXP3+ Treg erhöhte, die sind niederzuwerfen regulieren die Tätigkeit der pathogenen T-Zellen, die MS verursachen. Zunehmende wissenschaftliche Entdeckungen dazugehörig verminderte Niveaus der Zellenantworten FOXP3+ Treg mit der Pathogenese und der Weiterentwicklung von MS und von anderen autoimmunen Krankheiten wie rheumatoid Arthritis (RA), psoriasis und Krankheit Crohns. Zusätzlich zum MS hat die Firma geöffnete neue Drogeuntersuchungsanwendungen (IND) mit der FDA für klinische Auswertung der TCR Peptid-gegründeten immun-gegründeten Therapien für RA und psoriasis.

IR103 wird basiert auf der patentierten vollständig-inaktivierten Virustechnologie der Firma, vom Dr. Jonas Salk Co-erfunden und gezeigt, um in den umfangreichen klinischen Studien von REMUNE®, der HIV-Produktanwärter des ersten Erzeugung der Firma sicher und immunisierend zu sein an. IR103 ist eine stärkere Formulierung, die sein vollständig-inaktiviertes Antigen mit einem Chemiefasergewebe Abgabe-wie Agonist des Empfängers (Tlr-9) kombiniert, um erhöhte HIV-spezifische immune Antworten zu verursachen. Die Firma prüft z.Z. IR103 in klinischen Studien Zweiphasen-II als first-line Behandlung auf die Droge-naïve HIV-angesteckten Einzelpersonen nicht schon geeignet auf antiretroviral Therapie entsprechend gegenwärtigen medizinischen Richtlinien.

Besuchen Sie bitte die immunes Wartekorporation an www.imnr.com

Diese Nachrichtenfreigabe enthält das Vorwärts-Schauen von Aussagen. Vorwärts-schauend werden Aussagen häufig durch Formen von Wörtern wie signalisiert, wenn, konnten, Macht, Plan, Projektion, Prognose, zu erwarten, Anleitung, Potential und sich Entwickeln werden. Tatsächliche Resultate konnten von jenen erwarteten wegen einer Vielzahl der Gefahrenfaktoren materiell schwanken und umfassen, ob die Firma da ein gehendes Interesse fortfährt und erfolgreich Erträge von den Finanzierungstätigkeiten aufwirft, die genügend sind, Betriebe und zusätzliche klinische Versuche von NeuroVaxTM oder von IR103, die Ungewißheit zu finanzieren der erfolgreichen Beendigung irgend solcher klinischer Versuche, die Tatsache, daß die Firma nicht gefolgt hat, mit, irgendeine Droge, die Gefahr, die NeuroVaxTM oder IR103 nicht sein konnten wirkungsvoll entweder als therapeutischer oder vorbeugender Impfstoff, ob zukünftige Versuche und geleitet werden, ob in den Handel zu bringen die Resultate solcher Versuche mit den Resultaten NeuroVaxTM oder IR103 in den preclinical Versuchen und/oder in den früheren klinischen Versuchen übereinstimmen. Ein umfangreicherer Satz Gefahren wird in den der immunes Wartesek-Archivierungen korporation einschließlich festgelegt, aber begrenzt nicht auf, in seinem jährlichen Bericht über Form 10-K für das Jahr beendet worden Dezember 31, 2004 und seine folgenden vierteljährlichen Reports, die auf Form 10-Q vorgelegt werden. Die Firma geht keine Verbindlichkeit ein, die Resultate dieser Vorwärts-schauenden Aussagen zu aktualisieren, um Fälle oder Umstände nach heutigem Tag zu reflektieren oder das Auftreten der unvorhergesehenen Fälle zu reflektieren.

REMUNE® ist ein eingetragenes eingetragenes Warenzeichen der immunes Wartekorporation. NeuroVaxTM ist ein eingetragenes Warenzeichen der immunes Wartekorporation.

[oski]

Time Shares Price
16:00:31 4,000 0.1390
16:00:28 5,500 0.1390
16:00:28 2,200 0.1390
16:00:28 10,000 0.1390
16:00:28 20,000 0.1390
16:00:22 4,500 0.1380
15:59:54 10,000 0.1390
15:59:51 3,850 0.1350
15:59:34 1,500 0.1390
15:59:14 500 0.1390
15:58:12 12,000 0.1390
15:58:01 1,000 0.1390
15:57:59 1,000 0.1360
15:57:53 4,000 0.1390
15:57:32 10,000 0.1390
15:57:32 1,350 0.1400
15:57:32 4,676 0.1400
15:57:32 3,974 0.1400
15:57:22 1,000 0.1370
15:57:12 10,000 0.1390
15:57:12 9,000 0.1400
15:57:12 10,000 0.1390
15:57:12 1,000 0.1400
15:57:12 6,000 0.1400
15:57:12 4,000 0.1400
15:57:04 1,000 0.1360
15:56:44 500 0.1350
15:56:42 10,000 0.1350
15:56:38 5,000 0.1350
15:56:34 25,000 0.1350
15:56:30 25,000 0.1350
15:56:18 5,000 0.1350
15:56:15 17,000 0.1350
15:55:31 7,500 0.1350
15:55:23 9,500 0.1350
15:55:19 500 0.1350
15:55:16 2,500 0.1330
15:55:15 700 0.1350
15:55:12 500 0.1330
15:54:23 58,500 0.1330
15:54:09 100 0.1350
15:53:44 20,000 0.1350
15:53:37 700 0.1350
15:53:33 2,925 0.1350
15:53:33 5,000 0.1350
15:53:33 10,000 0.1350
15:53:21 5,000 0.1350
15:52:32 16,000 0.1330
15:50:03 9,500 0.1350
15:49:01 1,000 0.1350
15:48:56 4,000 0.1350
15:48:46 500 0.1350
15:48:45 2,500 0.1310
15:47:35 1,250 0.1310
15:47:20 2,500 0.1310
15:47:03 10,000 0.1310
15:46:39 500 0.1310
15:45:35 10,000 0.1310
15:41:50 4,000 0.1310
15:41:29 500 0.1310
15:39:06 400 0.1310
15:39:06 5,000 0.1310
15:37:28 2,500 0.1310
15:33:59 9,500 0.1310
15:33:53 500 0.1310
15:32:51 500 0.1310
15:32:46 500 0.1310
15:30:15 2,500 0.1310
15:29:41 2,000 0.1300
15:29:37 20,000 0.1300
15:29:24 27,000 0.1300
15:29:21 8,000 0.1300
15:28:55 5,000 0.1300
15:28:55 5,000 0.1310
15:28:55 20,000 0.1300
15:28:55 15,000 0.1310
15:28:50 13,000 0.1350
15:28:44 10,000 0.1349
15:28:44 10,000 0.1350
15:28:44 5,000 0.1350
15:28:44 9,000 0.1350
15:28:29 1,700 0.1350
15:28:19 5,000 0.1330
15:26:40 20,000 0.1310
15:26:18 4,000 0.1310
15:24:41 20,000 0.1300
15:22:32 6,000 0.1350
15:20:29 40,000 0.1330
15:20:29 6,100 0.1350
15:20:29 5,000 0.1350
15:14:52 6,500 0.1350
15:14:36 160 0.1300
15:13:34 500 0.1350
15:07:44 500 0.1300
15:04:39 10,000 0.1300
15:04:04 1,000 0.1330
15:04:04 1,000 0.1350
15:04:00 2,500 0.1350
15:04:00 2,500 0.1330
15:03:57 15,000 0.1330
14:58:04 2,000 0.1330
14:57:24 20,000 0.1350
14:57:24 3,800 0.1320
14:57:06 35,000 0.1330
14:57:06 15,000 0.1350
14:57:06 19,600 0.1350
14:57:06 400 0.1350
14:56:21 350 0.1300
14:50:23 20,000 0.1330
14:50:23 2,500 0.1340
14:50:23 10,000 0.1350
14:47:21 10,000 0.1300
14:45:57 400 0.1300
14:45:01 10,000 0.1300
14:41:49 4,500 0.1300
14:41:43 100 0.1270
14:41:36 500 0.1300
14:38:53 35,000 0.1270
14:38:53 19,600 0.1250
14:38:45 5,000 0.1300
14:38:45 5,000 0.1250
14:37:07 10,000 0.1300
14:37:07 10,000 0.1250
14:33:16 1,350 0.1300
14:32:57 500 0.1300
14:32:29 7,000 0.1300
14:32:13 4,900 0.1300
14:31:36 20,000 0.1300
14:31:36 2,000 0.1300
14:29:31 10,000 0.1300
14:27:54 5,000 0.1300
14:27:52 10,000 0.1300
14:27:22 20,000 0.1300
14:26:25 5,000 0.1300
14:21:45 3,000 0.1300
14:21:09 18,000 0.1300
14:21:08 4,000 0.1300
14:20:13 1,000 0.1300
14:16:55 58,000 0.1300
14:16:55 82,000 0.1280
14:16:43 5,000 0.1280
14:15:21 1,000 0.1300
14:13:12 32,000 0.1300
14:13:12 32,000 0.1270
14:12:51 5,000 0.1270
14:11:39 2,150 0.1300
14:11:31 500 0.1300
14:10:39 1,000 0.1270
14:06:54 15,000 0.1300
13:58:06 5,000 0.1300
13:57:42 700 0.1300
13:55:03 10,000 0.1290
13:55:00 41,590 0.1290
13:53:31 500 0.1300
13:53:26 10,000 0.1290
13:52:31 38,461 0.1300
13:48:47 17,515 0.1300
13:45:54 36,000 0.1300
13:44:23 7,800 0.1270
13:44:06 5,000 0.1300
13:43:49 500 0.1300
13:42:35 500 0.1300
13:42:24 3,500 0.1300
13:42:24 5,000 0.1300
13:42:15 1,500 0.1300
13:42:12 5,000 0.1310
13:42:10 10,000 0.1300
13:41:38 500 0.1300
13:41:38 16,800 0.1300
13:41:32 500 0.1300
13:40:38 5,000 0.1330
13:40:38 5,000 0.1340
13:34:20 500 0.1300
13:32:29 10,000 0.1310
13:31:53 10,000 0.1310
13:31:32 10,000 0.1310
13:31:32 9,500 0.1300
13:31:25 50,000 0.1310
13:31:25 50,000 0.1300
13:28:47 50,000 0.1300
13:26:32 1,200 0.1350
13:26:32 1,200 0.1320
13:25:24 15,000 0.1310
13:25:24 15,000 0.1300
13:24:39 1,500 0.1340
13:24:39 1,000 0.1300
13:24:39 500 0.1300
13:24:34 5,000 0.1300
13:24:34 20,000 0.1300
13:24:27 30,000 0.1300
13:20:48 1,000 0.1300
13:20:32 9,500 0.1300
13:20:18 500 0.1300
13:16:12 3,000 0.1300
13:16:02 18,000 0.1340
13:16:01 3,000 0.1300
13:15:49 2,000 0.1300
13:15:41 1,000 0.1340
13:15:36 1,000 0.1340
13:14:22 3,000 0.1300
13:12:09 5,000 0.1300
13:11:52 23,000 0.1340
13:11:51 5,000 0.1300
13:11:30 9,500 0.1300
13:11:22 500 0.1300
13:05:50 10,000 0.1300
13:04:15 2,000 0.1340
13:00:48 2,000 0.1300
13:00:48 5,000 0.1300
13:00:48 20,000 0.1300
13:00:48 3,100 0.1300
13:00:48 20,000 0.1300
13:00:48 10,500 0.1300
13:00:48 1,000 0.1340
12:58:51 20,000 0.1250
12:57:50 3,800 0.1340
12:57:46 500 0.1340
12:56:04 4,000 0.1340
12:53:27 1,500 0.1300
12:52:07 100,000 0.1250
12:51:52 300 0.1260
12:51:20 15,000 0.1250
12:50:41 500 0.1290
12:50:26 22,000 0.1250
12:48:34 2,200 0.1290
12:48:33 400 0.1290
12:47:48 500 0.1290
12:47:40 500 0.1290
12:46:53 4,500 0.1290
12:46:48 500 0.1290
12:45:34 12,000 0.1280
12:45:34 6,000 0.1290
12:45:20 3,000 0.1280
12:45:20 10,000 0.1280
12:44:18 58,000 0.1250
12:44:18 7,000 0.1300
12:44:18 650 0.1280
12:40:45 5,000 0.1350
12:40:45 20,000 0.1310
12:40:45 5,000 0.1340
12:40:42 5,000 0.1300
12:40:41 5,000 0.1300
12:40:41 5,000 0.1310
12:40:30 4,500 0.1300
12:39:57 10,000 0.1300
12:36:33 3,000 0.1310
12:36:33 3,000 0.1300
12:36:30 125 0.1300
12:36:05 5,700 0.1300
12:36:05 3,400 0.1300
12:36:00 6,800 0.1300
12:35:58 18,200 0.1290
12:35:02 5,000 0.1260
12:35:02 5,000 0.1263
12:34:27 10,000 0.1270
12:34:21 2,500 0.1290
12:34:17 500 0.1290
12:34:09 10,600 0.1270
12:31:55 49,500 0.1290
12:31:51 500 0.1290
12:31:31 9,500 0.1290
12:31:14 500 0.1290
12:28:56 2,500 0.1250
12:28:56 32,500 0.1250
12:28:56 2,500 0.1251
12:28:51 1,000 0.1270
12:28:48 5,000 0.1250
12:28:22 13,000 0.1250
12:27:24 6,800 0.1250
12:27:23 3,500 0.1250
12:27:01 500 0.1250
12:26:45 15,000 0.1250
12:26:40 500 0.1250
12:25:29 2,500 0.1270
12:25:24 9,500 0.1250
12:25:23 200 0.1300
12:25:21 500 0.1250
12:24:45 2,000 0.1300
12:24:43 500 0.1300
12:24:39 19,500 0.1280
12:24:35 14,000 0.1300
12:24:28 500 0.1280
12:23:57 23,000 0.1290
12:23:57 27,000 0.1290
12:22:41 5,000 0.1300
12:22:37 15,000 0.1310
12:22:37 15,000 0.1300
12:22:35 5,000 0.1300
12:22:34 5,000 0.1300
12:21:55 5,000 0.1300
12:21:28 15,000 0.1300
12:21:28 4,500 0.1300
12:21:28 1,000 0.1300
12:21:28 107 0.1300
12:21:28 20,000 0.1300
12:21:28 27,000 0.1300
12:21:28 10,000 0.1300
12:21:28 20,000 0.1300
12:21:28 1,600 0.1300
12:21:27 5,000 0.1300
12:20:40 10,000 0.1300
12:17:01 100 0.1340
12:17:01 100 0.1350
12:16:58 16,000 0.1340
12:16:58 9,500 0.1350
12:16:58 6,500 0.1350
12:13:42 20,000 0.1310
12:12:41 19,000 0.1300
12:10:46 7,000 0.1310
12:10:46 14,500 0.1310
12:10:29 500 0.1300
12:08:17 500 0.1300
12:08:10 2,000 0.1350
12:07:37 4,500 0.1300
12:07:02 500 0.1300
12:05:54 6,000 0.1300
12:04:53 1,000 0.1310
12:04:50 2,000 0.1310
12:04:50 2,000 0.1350
12:04:44 1,000 0.1350
12:04:44 1,000 0.1310
12:04:41 1,000 0.1310
12:04:41 1,000 0.1350
12:03:52 4,000 0.1350
12:01:58 2,500 0.1330
12:01:55 2,500 0.1350
12:01:39 1,000 0.1350
12:01:20 500 0.1350
11:58:48 5,000 0.1350
11:58:21 8,498 0.1300
11:58:19 8,498 0.1310
11:54:16 10,000 0.1310
11:54:06 18,000 0.1310
11:53:26 6,000 0.1350
11:53:26 4,000 0.1320
11:53:20 6,000 0.1320
11:52:32 7,000 0.1320
11:51:24 20,000 0.1310
11:51:24 3,979 0.1300
11:51:24 1,000 0.1300
11:51:24 3,836 0.1300
11:51:24 3,000 0.1300
11:51:24 5,000 0.1300
11:51:16 3,000 0.1350
11:50:20 1,300 0.1320
11:50:19 9,500 0.1300
11:50:14 500 0.1300
11:49:49 3,500 0.1350
11:49:47 20,000 0.1350
11:49:37 500 0.1350
11:46:05 6,500 0.1350
11:46:05 6,500 0.1350
11:45:41 63,570 0.1310
11:45:35 5,000 0.1310
11:44:48 2,500 0.1350
11:43:36 5,000 0.1390
11:43:36 5,000 0.1350
11:41:15 20,000 0.1390
11:41:15 4,500 0.1350
11:40:29 15,000 0.1350
11:39:33 26,136 0.1350
11:39:00 6,155 0.1350
11:38:49 4,800 0.1390
11:38:39 100 0.1390
11:38:34 100 0.1390
11:38:30 5,000 0.1340
11:38:30 5,000 0.1390
11:36:22 5,175 0.1390
11:36:04 10,700 0.1390
11:34:23 145 0.1390
11:32:07 30,000 0.1390
11:31:43 500 0.1380
11:29:29 2,800 0.1390
11:29:01 1,400 0.1390
11:29:01 500 0.1350
11:28:39 5,000 0.1350
11:26:53 5,025 0.1350
11:25:44 500 0.1350
11:24:23 750 0.1350
11:24:20 10,000 0.1350
11:24:20 1,500 0.1350
11:24:20 13,000 0.1320
11:24:20 4,000 0.1350
11:24:20 7,500 0.1350
11:24:20 10,000 0.1320
11:23:34 1,200 0.1350
11:23:34 1,200 0.1320
11:23:25 5,000 0.1320
11:23:25 5,000 0.1350
11:21:22 1,975 0.1380
11:19:48 175,000 0.1370
11:19:42 5,000 0.1310
11:18:05 20,000 0.1390
11:17:07 25,000 0.1310
11:12:34 25,000 0.1380
11:11:20 1,400 0.1380
11:09:46 20,000 0.1380
11:09:46 20,000 0.1360
11:09:19 71,250 0.1390
11:09:19 25,075 0.1400
11:09:19 10,000 0.1380
11:09:19 10,000 0.1360
11:09:19 16,875 0.1400
11:09:19 1,800 0.1400
11:09:17 8,500 0.1350
11:09:17 250 0.1350
11:05:49 4,500 0.1350
11:04:24 6,000 0.1360
11:04:15 3,000 0.1380
11:04:15 12,000 0.1380
11:04:15 12,000 0.1360
11:04:15 7,000 0.1360
11:04:15 7,000 0.1380
11:04:09 5,000 0.1370
11:04:00 10,000 0.1370
11:02:05 100,000 0.1300
11:02:02 2,000 0.1350
11:02:02 100,000 0.1350
11:00:42 10,000 0.1380
11:00:35 5,000 0.1360
11:00:07 5,000 0.1360
10:59:24 500 0.1360
10:59:17 500 0.1360
10:58:42 2,500 0.1360
10:58:39 8,800 0.1350
10:58:06 500 0.1360
10:58:06 4,500 0.1360
10:58:06 5,000 0.1350
10:58:03 8,000 0.1360
10:58:03 20,000 0.1360
10:58:02 8,000 0.1350
10:58:02 20,000 0.1350
10:57:47 2,000 0.1370
10:57:22 25,000 0.1360
10:57:22 19,900 0.1300
10:55:14 100,000 0.1360
10:55:14 100,000 0.1370
10:54:40 10,000 0.1300
10:54:40 10,000 0.1370
10:54:31 10,000 0.1300
10:54:30 10,000 0.1370
10:53:56 100 0.1370
10:53:56 100 0.1300
10:53:53 6,500 0.1400
10:53:53 6,500 0.1360
10:52:55 3,000 0.1370
10:52:55 10,000 0.1370
10:52:52 30,000 0.1360
10:52:36 1,000 0.1370
10:52:36 4,500 0.1370
10:52:31 500 0.1370
10:50:34 500 0.1380
10:48:46 200 0.1320
10:48:46 200 0.1300
10:48:46 3,000 0.1350
10:48:42 25,000 0.1350
10:46:32 2,690 0.1350
10:46:10 8,000 0.1350
10:46:04 5,000 0.1350
10:45:46 10,000 0.1350
10:45:40 500 0.1380
10:45:40 500 0.1350
10:45:37 12,793 0.1350
10:45:37 11,000 0.1300
10:44:34 100 0.1300
10:44:34 8,500 0.1300
10:44:24 100 0.1300
10:44:15 15,000 0.1310
10:44:15 10,000 0.1310
10:44:14 10,000 0.1310
10:44:14 100 0.1300
10:44:14 10,000 0.1310
10:44:08 100 0.1300
10:44:00 7,500 0.1300
10:43:58 100 0.1300
10:43:57 500 0.1300
10:43:48 100 0.1300
10:43:38 100 0.1300
10:43:33 100 0.1300
10:43:23 100 0.1300
10:43:21 30,000 0.1310
10:43:13 100 0.1300
10:43:03 100 0.1300
10:42:56 9,964 0.1310
10:42:56 4,000 0.1300
10:42:56 5,964 0.1300
10:42:54 5,000 0.1300
10:42:54 10,000 0.1310
10:42:54 5,000 0.1340
10:42:52 100 0.1300
10:42:47 100 0.1300
10:42:37 100 0.1300
10:42:27 100 0.1300
10:42:15 25,000 0.1350
10:42:13 7,500 0.1340
10:40:43 12,000 0.1350
10:40:43 7,000 0.1350
10:40:43 12,000 0.1350
10:40:15 100 0.1300
10:40:05 100 0.1300
10:40:04 10,000 0.1350
10:40:04 4,964 0.1300
10:39:55 100 0.1300
10:39:44 100 0.1300
10:39:43 650 0.1350
10:39:42 1,100 0.1350
10:39:39 100 0.1300
10:39:28 100 0.1300
10:39:19 100 0.1380
10:39:17 9,000 0.1380
10:39:08 100 0.1380
10:38:41 46,400 0.1400
10:38:18 1,000 0.1400
10:37:22 10,000 0.1380
10:37:16 10,000 0.1390
10:37:07 1,000 0.1400
10:37:07 33,000 0.1400
10:37:07 5,000 0.1400
10:37:07 7,822 0.1400
10:37:07 50,000 0.1400
10:37:07 33,000 0.1400
10:37:07 1,000 0.1400
10:37:07 29,555 0.1400
10:37:06 50,000 0.1400
10:37:06 20,000 0.1400
10:37:05 35,000 0.1400
10:37:04 5,000 0.1400
10:36:19 4,000 0.1390
10:35:56 500 0.1400
10:34:56 125 0.1400
10:34:45 2,964 0.1400
10:34:45 1,000 0.1400
10:34:45 2,178 0.1400
10:34:44 13,858 0.1400
10:34:44 20,000 0.1390
10:34:42 10,000 0.1390
10:33:55 3,000 0.1400
10:33:24 32,700 0.1390
10:32:46 15,000 0.1380
10:32:46 15,000 0.1400
10:32:40 25,000 0.1400
10:32:36 1,700 0.1390
10:32:26 25,000 0.1400
10:32:25 3,300 0.1400
10:32:25 3,300 0.1390
10:32:22 25,000 0.1400
10:31:53 2,300 0.1400
10:31:53 2,300 0.1380
10:31:32 5,000 0.1400
10:31:22 25,000 0.1400
10:31:22 25,000 0.1400
10:31:15 25,000 0.1400
10:27:28 1,000 0.1400
10:27:28 1,000 0.1380
10:26:37 1,000 0.1400
10:26:37 1,000 0.1380
10:26:06 7,500 0.1400
10:26:06 750 0.1400
10:26:06 5,000 0.1400
10:26:06 12,000 0.1400
10:26:06 5,500 0.1400
10:26:06 5,500 0.1380
10:25:40 500 0.1400
10:25:23 11,900 0.1400
10:25:15 5,000 0.1400
10:24:48 5,000 0.1400
10:24:45 7,000 0.1400
10:24:45 10,000 0.1400
10:24:40 10,000 0.1400
10:24:40 10,000 0.1410
10:24:28 4,500 0.1410
10:24:19 4,500 0.1410
10:24:10 500 0.1410
10:24:07 900 0.1410
10:24:07 7,342 0.1410
10:24:07 8,242 0.1400
10:24:05 100,000 0.1400
10:24:04 9,100 0.1400
10:24:04 9,100 0.1410
10:23:26 15,000 0.1400
10:23:22 5,000 0.1440
10:23:07 7,500 0.1440
10:23:06 10,000 0.1440
10:21:59 25,000 0.1460
10:21:59 5,000 0.1440
10:21:55 10,000 0.1440
10:21:35 29,500 0.1440
10:21:18 100 0.1400
10:21:08 5,000 0.1400
10:21:08 20,000 0.1400
10:21:08 9,550 0.1400
10:21:08 20,000 0.1400
10:21:08 10,000 0.1400
10:21:07 100 0.1400
10:21:05 25,000 0.1400
10:21:04 25,000 0.1400
10:20:57 100 0.1400
10:20:52 100 0.1400
10:20:45 500 0.1400
10:20:42 100 0.1400
10:20:39 3,300 0.1400
10:20:39 5,000 0.1400
10:20:39 2,750 0.1400
10:20:31 5,000 0.1390
10:20:31 100 0.1390
10:20:31 5,000 0.1390
10:20:28 11,000 0.1390
10:20:28 4,000 0.1390
10:20:21 100 0.1390
10:20:16 100 0.1390
10:20:16 1,000 0.1390
10:20:06 100 0.1390
10:19:57 7,000 0.1390
10:19:56 19,500 0.1350
10:19:56 100 0.1390
10:19:49 10,000 0.1360
10:19:49 25,000 0.1360
10:19:47 300 0.1360
10:19:46 10,000 0.1350
10:19:45 100 0.1360
10:19:44 5,000 0.1350
10:19:44 12,400 0.1350
10:19:40 5,000 0.1360
10:19:40 1,000 0.1360
10:19:40 4,000 0.1351
10:19:40 100 0.1360
10:19:39 10,000 0.1350
10:19:30 100 0.1360
10:19:20 100 0.1360
10:19:09 100 0.1360
10:19:05 500 0.1350
10:18:59 100 0.1360
10:18:50 100 0.1360
10:18:46 4,200 0.1360
10:18:46 4,200 0.1350
10:18:44 100 0.1360
10:18:39 10,000 0.1360
10:18:39 10,000 0.1350
10:18:34 100 0.1360
10:18:24 100 0.1360
10:18:16 1,500 0.1360
10:18:14 100 0.1360
10:18:12 3,000 0.1360
10:18:12 3,000 0.1350
10:18:08 100 0.1360
10:18:07 500 0.1360
10:17:58 100 0.1360
10:17:48 100 0.1360
10:17:45 5,000 0.1350
10:17:38 100 0.1360
10:17:28 100 0.1360
10:17:23 100 0.1360
10:17:18 5,000 0.1300
10:17:13 100 0.1360
10:17:12 1,500 0.1360
10:17:02 100 0.1360
10:16:53 100 0.1360
10:16:52 500 0.1360
10:16:42 100 0.1360
10:16:32 4,000 0.1350
10:16:28 500 0.1350
10:16:28 4,499 0.1350
10:16:28 501 0.1350
10:16:25 10,000 0.1350
10:16:21 10,000 0.1340
10:16:20 6,500 0.1310
10:16:18 20,000 0.1310
10:16:16 10,000 0.1360
10:16:13 15,000 0.1350
10:16:11 15,000 0.1360
10:15:46 3,000 0.1360
10:15:46 3,000 0.1300
10:15:24 5,000 0.1390
10:15:24 5,000 0.1350
10:15:18 400 0.1390
10:15:18 400 0.1300
10:14:51 17,000 0.1350
10:14:51 17,000 0.1390
10:14:51 5,000 0.1350
10:14:49 5,000 0.1390
10:14:30 10,000 0.1390
10:13:46 8,200 0.1390
10:13:46 3,200 0.1400
10:13:44 50,000 0.1390
10:13:43 50,000 0.1350
10:13:41 5,000 0.1390
10:13:38 5,000 0.1350
10:13:28 5,000 0.1390
10:13:26 3,000 0.1390
10:13:19 10,000 0.1350
10:13:15 500 0.1390
10:13:14 2,500 0.1395
10:13:09 500 0.1400
10:13:05 49,500 0.1395
10:12:59 1,000 0.1400
10:12:55 6,000 0.1400
10:12:55 4,000 0.1400
10:12:55 10,000 0.1390
10:12:55 10,000 0.1395
10:12:49 60,000 0.1400
10:12:46 500 0.1400
10:12:46 5,000 0.1390
10:12:46 450 0.1400
10:12:46 6,550 0.1400
10:12:46 1,550 0.1390
10:12:43 8,450 0.1390
10:12:43 8,450 0.1400
10:12:40 41,550 0.1390
10:12:37 41,550 0.1400
10:12:30 100,000 0.1400
10:12:30 1,000 0.1390
10:12:30 5,000 0.1390
10:12:30 32,050 0.1390
10:12:30 33,500 0.1390
10:12:30 20,000 0.1390
10:12:30 8,450 0.1390
10:12:21 500 0.1400
10:12:21 5,500 0.1400
10:12:21 5,500 0.1390
10:12:21 7,000 0.1390
10:12:21 7,000 0.1400
10:12:20 285 0.1400
10:12:18 4,600 0.1400
10:12:11 400 0.1390
10:12:11 400 0.1400
10:12:09 18,000 0.1390
10:12:09 2,000 0.1390
10:12:09 20,000 0.1400
10:12:07 20,000 0.1400
10:12:05 10,000 0.1400
10:11:56 20,000 0.1400
10:11:51 20,000 0.1400
10:11:51 8,000 0.1390
10:11:51 16,000 0.1400
10:11:48 8,000 0.1390
10:11:45 2,000 0.1400
10:11:45 2,000 0.1390
10:11:43 9,500 0.1400
10:11:41 500 0.1390
10:11:34 2,500 0.1400
10:11:34 4,500 0.1400
10:11:34 5,700 0.1400
10:11:34 8,000 0.1400
10:11:27 10,000 0.1380
10:11:21 500 0.1380
10:11:20 10,000 0.1300
10:11:19 571 0.1380
10:11:10 500 0.1350
10:11:07 5,000 0.1350
10:10:51 500 0.1350
10:10:44 10,000 0.1350
10:10:44 17,500 0.1340
10:10:44 3,800 0.1350
10:10:41 8,500 0.1350
10:10:40 9,500 0.1330
10:10:31 500 0.1350
10:10:30 500 0.1330
10:10:27 19,500 0.1330
10:10:27 5,000 0.1340
10:10:16 500 0.1330
10:10:12 20,000 0.1350
10:10:10 15,000 0.1340
10:10:05 5,000 0.1340
10:09:46 5,000 0.1340
10:09:43 20,000 0.1340
10:09:28 15,000 0.1300
10:09:20 3,800 0.1300
10:09:19 10,000 0.1300
10:09:19 5,000 0.1300
10:09:19 1,000 0.1300
10:09:19 500 0.1300
10:09:17 15,000 0.1300
10:09:13 20,000 0.1300
10:09:12 20,000 0.1300
10:09:05 10,000 0.1300
10:08:59 3,800 0.1310
10:08:59 22,365 0.1300
10:07:59 20,000 0.1300
10:07:54 50,000 0.1300
10:07:53 50,000 0.1300
10:07:37 5,000 0.1300
10:07:37 1,000 0.1300
10:07:33 5,000 0.1300
10:07:19 5,000 0.1300
10:07:05 7,000 0.1300
10:07:05 7,000 0.1300
10:07:02 5,000 0.1300
10:06:52 100 0.1300
10:06:52 5,000 0.1300
10:06:46 100 0.1300
10:06:36 100 0.1300
10:06:35 5,000 0.1250
10:06:35 5,000 0.1250
10:06:35 10,000 0.1250
10:06:35 10,000 0.1300
10:06:35 10,000 0.1300
10:06:31 1,000 0.1300
10:06:29 5,000 0.1250
10:06:29 5,000 0.1300
10:06:26 5,000 0.1300
10:06:16 100 0.1300
10:06:16 3,000 0.1300
10:06:16 4,000 0.1300
10:05:49 500 0.1300
10:05:34 2,750 0.1210
10:05:33 2,750 0.1250
10:04:57 15,000 0.1250
10:04:57 15,000 0.1210
10:03:44 10,000 0.1200
10:03:44 10,000 0.1320
10:03:43 10,000 0.1320
10:03:33 45,000 0.1300
10:02:58 10,000 0.1300
10:02:34 15,000 0.1200
10:02:22 5,000 0.1290
10:02:22 1,000 0.1300
10:02:12 5,000 0.1300
10:01:51 8,000 0.1300
10:01:51 2,000 0.1300
10:01:47 10,000 0.1300
10:01:40 10,000 0.1400
10:01:36 1,000 0.1300
10:01:36 14,000 0.1390
10:01:36 6,000 0.1390
10:01:36 5,000 0.1300
10:01:30 219,500 0.1300
10:01:27 200,000 0.1390
10:01:10 10,000 0.1395
10:01:10 10,000 0.1390
10:01:07 20,000 0.1390
10:01:07 20,000 0.1395
10:01:01 20,000 0.1400
10:01:01 5,000 0.1390
10:01:00 4,000 0.1300
10:01:00 7,500 0.1300
10:00:54 20,000 0.1350
10:00:33 200,000 0.1390
10:00:32 10,000 0.1400
10:00:30 40,000 0.1400
10:00:30 10,000 0.1400
10:00:29 100,000 0.1390
10:00:27 10,000 0.1390
10:00:27 10,000 0.1400
10:00:24 4,964 0.1400
10:00:24 44,501 0.1400
10:00:24 5,000 0.1390
10:00:24 20,000 0.1400
10:00:24 10,000 0.1400
10:00:24 2,000 0.1400
10:00:24 714 0.1400
10:00:24 1,000 0.1400
10:00:24 5,000 0.1400
10:00:24 15,000 0.1400
10:00:24 1,750 0.1400
10:00:24 20,000 0.1400
10:00:17 499 0.1400
10:00:17 499 0.1390
10:00:17 4,000 0.1390
10:00:17 5,000 0.1390
10:00:17 3,000 0.1390
10:00:17 5,000 0.1390
10:00:17 500 0.1390
10:00:17 7,000 0.1390
10:00:17 5,000 0.1390
10:00:17 4,400 0.1390
10:00:17 13,000 0.1390
10:00:17 1,000 0.1390
10:00:13 3,000 0.1400
10:00:13 500 0.1390
10:00:13 2,500 0.1390
10:00:13 3,000 0.1400
10:00:13 3,000 0.1390
10:00:11 5,000 0.1400
10:00:11 10,000 0.1390
10:00:11 5,000 0.1400
10:00:02 10,000 0.1400
10:00:01 8,000 0.1400
09:59:47 20,000 0.1390
09:59:47 20,000 0.1400
09:59:42 10,000 0.1400
09:59:41 25,000 0.1400
09:59:38 8,000 0.1400
09:59:38 8,000 0.1390
09:59:35 5,000 0.1390
09:59:35 2,000 0.1390
09:59:35 10,000 0.1400
09:59:35 3,000 0.1390
09:59:34 10,000 0.1400
09:59:07 500 0.1400
09:59:07 5,000 0.1400
09:59:07 6,325 0.1400
09:59:04 500 0.1400
09:59:03 10,000 0.1350
09:59:01 10,000 0.1400
09:59:01 2,501 0.1400
09:59:01 10,000 0.1400
09:58:59 99,500 0.1400
09:58:39 3,000 0.1390
09:58:39 3,000 0.1400
09:58:39 500 0.1390
09:58:24 500 0.1400
09:58:10 20,000 0.1400
09:58:00 500 0.1400
09:57:57 500 0.1390
09:57:52 50,000 0.1500
09:57:52 10,000 0.1500
09:57:52 5,000 0.1500
09:57:52 1,100 0.1500
09:57:51 1,000 0.1400
09:57:51 20,000 0.1500
09:57:51 8,000 0.1400
09:57:51 2,500 0.1400
09:57:51 20,871 0.1500
09:57:48 10,000 0.1400
09:57:47 10,000 0.1400
09:57:36 2,000 0.1400
09:57:36 4,000 0.1375
09:57:36 2,000 0.1400
09:57:21 5,000 0.1350
09:57:21 3,000 0.1350
09:57:21 3,000 0.1370
09:57:15 5,642 0.1350
09:57:15 94,678 0.1350
09:57:15 4,358 0.1350
09:57:05 15,000 0.1340
09:57:05 15,000 0.1350
09:57:03 5,000 0.1350
09:56:55 500 0.1350
09:56:44 5,000 0.1350
09:56:42 500 0.1350
09:56:41 500 0.1350
09:56:35 500 0.1350
09:56:33 12,500 0.1300
09:56:31 500 0.1350
09:56:26 20,000 0.1290
09:56:16 5,000 0.1300
09:56:14 26,000 0.1300
09:56:14 100,000 0.1300
09:56:14 5,000 0.1300
09:56:14 35,000 0.1300
09:56:14 2,000 0.1300
09:56:14 5,000 0.1300
09:56:14 5,000 0.1300
09:56:14 10,700 0.1300
09:56:14 3,000 0.1300
09:56:14 25,000 0.1300
09:56:14 4,000 0.1300
09:56:14 1,500 0.1300
09:56:14 20,000 0.1300
09:56:14 10,000 0.1300
09:56:14 5,000 0.1300
09:56:14 10,000 0.1300
09:56:14 3,247 0.1300
09:56:14 10,000 0.1300
09:56:14 20,000 0.1300
09:56:14 15,000 0.1300
09:55:56 10,000 0.1300
09:55:45 10,000 0.1290
09:55:45 10,000 0.1300
09:55:33 500 0.1300
09:55:32 5,002 0.1300
09:55:32 5,002 0.1290
09:55:31 500 0.1300
09:55:27 10,000 0.1220
09:55:26 500 0.1300
09:55:22 500 0.1300
09:55:21 6,500 0.1300
09:55:03 4,000 0.1220
09:54:58 3,500 0.1300
09:54:55 15,000 0.1300
09:54:55 9,751 0.1250
09:54:41 10,000 0.1200
09:54:41 10,000 0.1250
09:54:40 7,500 0.1250
09:54:38 5,000 0.1250
09:54:37 7,500 0.1220
09:54:26 40,000 0.1200
09:54:25 40,000 0.1190
09:54:20 10,000 0.1200
09:54:19 4,500 0.1200
09:54:17 19,500 0.1200
09:54:16 19,500 0.1190
09:53:26 2,000 0.1200
09:53:25 2,000 0.1200
09:53:25 20,000 0.1200
09:53:19 5,000 0.1200
09:53:17 500 0.1200
09:52:43 2,000 0.1200
09:52:39 2,000 0.1200
09:52:39 2,000 0.1170
09:52:32 6,000 0.1200
09:52:32 6,000 0.1170
09:52:21 200 0.1200
09:52:17 5,000 0.1200
09:52:17 5,000 0.1170
09:52:12 15,000 0.1190
09:52:06 7,140 0.1200
09:52:06 25,666 0.1200
09:52:06 1,499 0.1200
09:52:06 10,000 0.1200
09:52:06 10,000 0.1200
09:52:05 10,000 0.1200
09:52:05 24,334 0.1200
09:52:04 1,000 0.1170
09:52:04 4,000 0.1170
09:52:04 4,000 0.1200
09:52:04 1,000 0.1200
09:51:57 5,000 0.1200
09:51:57 100,000 0.1100
09:51:57 5,000 0.1200
09:51:57 1,000 0.1150
09:51:57 8,850 0.1150
09:51:57 20,000 0.1150
09:51:57 2,000 0.1150
09:51:57 15,000 0.1150
09:51:57 5,000 0.1200
09:51:57 4,300 0.1150
09:51:57 7,500 0.1150
09:51:57 5,000 0.1200
09:51:57 4,999 0.1190
09:51:43 5,000 0.1150
09:51:30 3,500 0.1110
09:51:26 5,000 0.1175
09:51:22 6,000 0.1150
09:51:22 11,500 0.1150
09:51:20 20,000 0.1150
09:51:17 25,000 0.1110
09:51:13 99,500 0.1150
09:51:05 45,000 0.1100
09:50:52 500 0.1150
09:50:46 5,000 0.1140
09:50:44 10,000 0.1150
09:50:31 5,000 0.1135
09:50:18 10,000 0.1100
09:50:18 10,000 0.1110
09:50:17 500 0.1150
09:50:16 10,000 0.1110
09:50:13 2,500 0.1100
09:50:12 3,000 0.1100
09:50:12 3,000 0.1110
09:50:12 2,500 0.1110
09:50:12 5,670 0.1100
09:50:11 5,670 0.1110
09:50:06 50,000 0.1110
09:50:06 50,000 0.1100
09:50:02 50,000 0.1100
09:50:01 10,000 0.1110
09:50:00 8,250 0.1110
09:50:00 23,508 0.1110
09:50:00 8,242 0.1110
09:49:47 2,500 0.1100
09:49:43 50,000 0.1110
09:49:42 50,000 0.1110
09:49:23 500 0.1150
09:49:12 7,500 0.1100
09:49:10 5,000 0.1100
09:48:47 5,000 0.1090
09:48:36 5,000 0.1100
09:48:29 30,000 0.1090
09:48:23 9,100 0.1070
09:48:23 15,900 0.1070
09:48:22 10,000 0.1080
09:48:22 10,000 0.1070
09:48:22 25,000 0.1080
09:48:19 10,000 0.1080
09:48:18 1,500 0.1100
09:48:18 4,500 0.1100
09:48:18 20,000 0.1070
09:48:17 20,000 0.1080
09:48:17 10,000 0.1070
09:48:17 69,500 0.1100
09:48:17 6,500 0.1100
09:48:17 7,500 0.1100
09:48:17 5,000 0.1100
09:48:11 500 0.1100
09:48:01 50,000 0.1080
09:48:00 50,000 0.1080
09:48:00 50,000 0.1070
09:47:57 2,500 0.1070
09:47:57 1,350 0.1100
09:47:57 1,150 0.1100
09:47:14 500 0.1100
09:46:49 500 0.1100
09:46:42 2,000 0.1100
09:46:36 1,500 0.1100
09:46:35 8,200 0.1100
09:46:31 5,000 0.1080
09:46:24 35,000 0.1070
09:46:22 500 0.1070
09:46:15 500 0.1070
09:46:02 500 0.1070
09:45:56 500 0.1070
09:45:45 500 0.1070
09:45:43 500 0.1070
09:45:43 500 0.1070
09:45:03 500 0.1070
09:44:07 5,000 0.1050
09:43:50 2,000 0.1050
09:43:36 20,000 0.1050
09:43:19 500 0.1050
09:43:13 5,000 0.1050
09:43:09 4,500 0.1040
09:42:56 500 0.1050
09:42:54 500 0.1050
09:42:42 25,000 0.1030
09:42:33 5,000 0.1050
09:42:31 10,000 0.1050
09:42:13 5,000 0.1050
09:42:12 60,000 0.1050
09:42:12 10,000 0.1040
09:42:00 10,000 0.1050
09:41:22 500 0.1030
09:41:19 500 0.1030
09:41:19 500 0.1030
09:41:17 500 0.1050
09:41:05 300 0.1040
09:40:53 5,000 0.1050
09:40:52 5,000 0.1050
09:40:52 1,000 0.1050
09:40:52 20,000 0.1050
09:40:50 6,300 0.1050
09:40:47 2,000 0.1050
09:40:34 10,000 0.1050
09:40:22 5,505 0.1050
09:40:21 2,500 0.1050
09:40:15 1,500 0.1050
09:40:15 1,500 0.1000
09:40:12 9,505 0.1050
09:40:12 10,000 0.1000
09:40:12 495 0.1050
09:40:08 4,900 0.1050
09:40:06 495 0.1000
09:40:06 495 0.1020
09:40:00 5,000 0.1000
09:39:58 5,000 0.1000
09:39:58 25,000 0.1000
09:39:01 500 0.1050
09:38:45 5,000 0.1000
09:38:45 5,000 0.1000
09:38:35 10,000 0.1000
09:38:35 7,800 0.1000
09:38:27 500 0.1000
09:38:16 500 0.1000
09:38:15 89,050 0.0990
09:38:15 8,450 0.0990
09:38:15 10,950 0.0990
09:38:01 3,000 0.1000
09:37:54 500 0.1000
09:37:06 10,000 0.0980
09:37:06 10,000 0.1000
09:36:55 3,000 0.1000
09:36:55 6,550 0.0990
09:36:55 2,000 0.0990
09:36:55 8,000 0.0990
09:36:55 2,000 0.1000
09:36:55 10,000 0.1000
09:36:55 3,000 0.0990
09:36:55 3,450 0.0990
09:36:55 8,000 0.1000
09:36:54 5,000 0.1000
09:36:49 5,000 0.1000
09:36:49 5,000 0.0990
09:36:43 40,000 0.1000
09:36:43 40,000 0.0990
09:36:42 40,000 0.1000
09:36:31 4,500 0.1000
09:36:25 500 0.1000
09:36:05 500 0.1000
09:36:03 500 0.1000
09:36:03 500 0.1000
09:35:36 5,000 0.1000
09:34:57 2,500 0.1000
09:34:51 15,000 0.1000
09:34:08 3,000 0.1000
09:34:08 3,000 0.0990
09:34:05 20,000 0.1000
09:34:05 20,000 0.0990
09:34:02 5,000 0.1000
09:34:02 5,000 0.0990
09:33:54 4,000 0.1000
09:33:54 10,000 0.1000
09:33:54 5,000 0.1000
09:33:40 500 0.1000
09:33:11 550 0.0990
09:33:11 550 0.1000
09:33:08 550 0.1000
09:32:58 5,000 0.1000
09:32:48 4,900 0.1010
09:32:43 100,000 0.1010
09:32:41 5,000 0.0980
09:32:41 5,000 0.1000
09:32:40 5,000 0.1000
09:32:36 5,000 0.1000
09:32:25 500 0.0990
09:32:13 52,500 0.0990
09:32:08 500 0.0990
09:31:56 2,000 0.0990
09:31:54 2,000 0.0990
09:31:50 2,000 0.0990
09:31:50 2,000 0.0965
09:31:49 5,000 0.0900
09:31:49 22,300 0.0900
09:31:49 50,000 0.0900
09:31:49 20,000 0.0900
09:31:49 20,000 0.0900
09:31:49 5,700 0.0900
09:31:48 27,800 0.0970
09:31:48 27,800 0.0990
09:31:48 3,000 0.0970
09:31:48 3,000 0.0990
09:31:44 10,000 0.0990
09:31:44 10,000 0.0900
09:31:36 12,500 0.0900
09:31:36 88,200 0.0860
09:31:36 88,200 0.0990
09:31:36 12,500 0.0990
09:31:35 5,800 0.0950
09:31:35 10,000 0.0950
09:31:32 5,000 0.0990
09:30:59 500 0.0900
09:30:58 5,000 0.0900
09:30:56 10,000 0.0900
09:30:36 3,000 0.0900
09:30:32 500 0.0900
09:30:28 10,000 0.0900
09:30:19 500 0.0900
09:30:14 5,000 0.0900
09:30:12 2,500 0.0860
09:30:12 8,500 0.0860
09:30:12 11,500 0.0860
09:30:12 10,000 0.0900
09:30:12 10,000 0.0900
09:30:10 2,500 0.0900
09:30:09 20,000 0.0900
09:30:08 2,000 0.0900
09:30:03 2,000 0.0860
09:21:45 5,000 0.0850
09:21:44 5,000 0.0850
ja leider wurde gedrückt sonst wäre die 0.2 drin gewesen

[oski]

The Immune Response Corporation (OTCBB:IMNR) is an immuno-pharmaceutical Company focused on developing products to treat autoimmune and infectious diseases. The Company`s lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.

NeuroVax(TM), which is based on the Company`s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong disease specific cell mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn`s disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.

IR103 is based on the Company`s patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company`s first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for treatment-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.

NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.

[can2]

würde mich nicht wundern, wenn das teil noch richtig abgeht, ähnlich wie damals biocurex oder calypte bio, hat auch keiner sich vorstellen können, das die über 1 USD steigen! immerhin wäre das lediglich eine marktkap. von etwa 66 mio usd!

geduld zahlt sich aus...

[oski]

ja can2 das wird nächste woche spannend

[oski]

1$

[can2]

tja wer weiß das schon, auf jeden fall traue ich dem teil viel zu, da das volumen stetig steigt, die news viel phantasie haben und die allgem. wirtschaftliche lage in usa besser wird, siehe zinspolitik! investoren sind wieder bereit zu investieren, ich meine damit die großinvestoren! bei 66 mio shares wäre 50cent doch ein witz!

lassen wir uns doch einfach mal überraschen, langfristig ist viel drin, immerhin phase2 und vielversprechende news...

[can2]

@oski

hoffe bist noch investiert?

ich sage nur

biocurex, biophan, calypte bio...ähnliche raketen!

[oski]

[posting]20.170.388 von can2 am 12.02.06 19:29:52[/posting]ja klar das war vorauszusehen das beim HIV sektor seit jahren nach dem wundermittel gesucht wird und IMNR grose chancen hat mitzureden.

[can2]

die nächsten wochen werden spannend sein...

Börse
NASDAQ OTC BB

Aktuell
0,16 USD

Zeit
13.02.06 15:32

Diff. Vortag
+15,11 %

Tages-Vol.
42.156,58

Gehandelte Stück
407.720

Geld
0,155

Brief
0,16

Zeit
13.02.06 15:23

Spread
3,125%

Geld Stk.
5.000

Brief Stk.
5.000

[can2]

sieht doch schon ganz nett aus!

[can2]

Börse
NASDAQ OTC BB

Aktuell
0,17 USD

Zeit
13.02.06 15:50

Diff. Vortag
+22,30 %

Tages-Vol.
205.046,62

Gehandelte Stück
1,5 Mio.

Geld
0,166

Brief
0,17

Zeit
13.02.06 15:45

Spread
2,353%

Geld Stk.
5.000

Brief Stk.
5.000

[can2]

das volumen ist ja heute nicht von schlechten eltern!

Börse
NASDAQ OTC BB

Aktuell
0,145 USD

Zeit
13.02.06 17:13

Diff. Vortag
+4,32 %

Tages-Vol.
869.495,44

Gehandelte Stück
5,8 Mio.

Geld
0,14

Brief
0,147

Zeit
13.02.06 17:11

Spread
4,762%

Geld Stk.
5.000

Brief Stk.
5.000

[oski]

starkes volumen 8`492`174
es riecht nach NEWS

[oski]

oh oh die shorties schneiden sich in die finger

[can2]

ich bin geduldig, hauptsache der chart ist intakt!zwei rauf einer runter!

lg

[spontanix]

hallöchen
schöne entwicklung wenn mal den long-chart ansehe könntes einen netten rebound geben
finds schön wenn man sowas sieht wie heute:
ffm 09:39:00 0,120 24.694

zocker kommen an bord

[can2]

@spontanix

ist der chart nicht zucker? hoffentlich wird das noch so eine rakete wie biocurex oder biophan?

spannend spannend!

[oski]

--------------------------------------------------------------------------------


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): February 8, 2006


The Immune Response Corporation
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware 000-18006 33-0255679
_____________________
(State or other jurisdiction _____________
(Commission ______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)

5931 Darwin Court, Carlsbad, California 92008
_________________________________
(Address of principal executive offices) ___________
(Zip Code)


Registrant’s telephone number, including area code: [phone]

Not Applicable
______________________________________________
Former name or former address, if changed since last report



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




--------------------------------------------------------------------------------

Top of the Form
Item 1.01 Entry into a Material Definitive Agreement.

On February 8, 2006 we entered into and consummated a Note Exchange Agreement and a Note Revision Agreement with Cheshire Associates LLC ("Cheshire"), which is an affiliate of our director and major stockholder Kevin Kimberlin. These agreements pertained to a secured convertible note previously issued by us and held by Cheshire, with a principal balance (before the agreements) of $5,740,928 (the "Mortgage Note").

Under the Note Exchange Agreement, we issued 53,425,204 shares of newly-issued common stock to Cheshire in exchange for $1,005,683.31 of principal and $62,820.77 of accrued interest on the Mortgage Note.

This transaction resulted in antidilution adjustments under the terms of some of our outstanding derivative securities. Most notably, as a result of "ratchet" antidilution provisions in the secured convertible debenture and common stock warrants held by Cornell Capital Partners, LP ("Cornell Capital"), the conversion price and exercise price of those securities were reduced to $0.02 per share. As a result the $500,000 outstanding principal balance of the debenture, which had previously been convertible into 791,765 shares of common stock (at $0.6315 per share), became convertible into 25,000,000 shares of common stock; and the warrants, which had previously been exercisable for 500,000 shares of common stock (at $0.924 per share), became exercisable for 23,100,000 shares of common stock.

We no longer have enough authorized but unissued shares of common stock to enable the conversion or exercise of Cornell Capital’s securities for these expanded numbers of shares of common stock. Indeed, the Note Exchange Agreement issuance necessitated even invading the share reserves which had been previously established to underlie most of our derivative securities, other than Cornell Capital’s previously-established share reserves.

Under the Note Revision Agreement, the maturity date of the Mortgage Note was extended from May 31, 2007 to January 1, 2009 and in consideration for that extension we reduced the conversion price of the remaining $4,735,244.69 principal amount of the Mortgage Note to $0.02 per share of common stock. Accrued interest on the Mortgage Note will also be convertible at $0.02 per share of common stock. Before the Note Exchange Agreement, the conversion price of the Mortgage Note had been $0.70 per share. The difference between conversion of $4,735,244.69 at $0.70 per share and conversion of $4,735,244.69 at $0.02 per share is 229,997,599 additional shares of common stock. We no longer have enough authorized but unissued shares of common stock to enable the conversion of the Mortgage Note into this expanded number of shares of common stock.

On February 9, 2006, we entered into and consummated a Securities Purchase Agreement with Qubit Holdings, LLC ("Qubit"). In exchange for $250,000 cash, we issued to Qubit a $250,000 promissory note, secured by substantially all of our assets, bearing interest at 8% per annum, maturing on January 1, 2008, and convertible into our common stock at $0.02 per share, plus 37,500,000 short-term warrants to purchase our common stock at $0.02 per share. In the Securities Purchase Agreement, Qubit also granted us the right to, until August 8, 2006, put to Qubit another $250,000 secured convertible note of like tenor and another 37,500,000 short-term warrants of like tenor, and to thereupon receive another $250,000 cash. We no longer have enough authorized but unissued shares of common stock to enable the conversion or exercise of the derivative securities issued or issuable to Qubit.

In addition to the securities described herein, Cheshire owned, before these transactions, 13,689,838 shares of our common stock and exercisable securities for another 19,923,548 shares of our common stock. In addition, Mr. Kimberlin and his affiliates owned, before these transactions, another 896,614 shares of our common stock and derivative securities overlying another 1,424,009 shares of our common stock.

By virtue of the transactions described above, nine outstanding warrants owned by Cheshire, which by their terms had been exercisable for an aggregate of 9,947,335 shares of common stock at a blended price of $1.05 per share, became exercisable instead for an aggregate of 31,727,025 shares of common stock at a blended price of $0.33 per share, via the operation of the warrants’ weighted-average antidilution adjustment provisions. None of the other derivative securities owned by Mr. Kimberlin or his affiliates experienced any antidilution adjustments as a result of the transactions described above.

Qubit is owned by certain trusts formed for the benefit of Mr. Kimberlin`s children. The trusts are, and Qubit is, managed by an independent trustee. Mr. Kimberlin disclaims beneficial ownership of all securities held by Qubit, because Mr. Kimberlin has no power to vote or dispose, or direct the voting or disposition, of any securities held by Qubit or such trusts.

On February 8, 2006, the closing sale price of our common stock as reported by the OTC Bulletin Board was $0.05 per share.






Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

See Item 1.01 above regarding the note issued to Qubit.






Item 3.02 Unregistered Sales of Equity Securities.

Note Exchange and Note Revision Agreements and Qubit Securities Purchase Agreement

See Item 1.01 above regarding the issuance of common stock and derivative securities and the revision of outstanding derivative securities, each of which transactions were not registered under the Securities Act but instead were exempt from registration by virtue of Section 4(2) of the Securities Act and Rule 506 under the Securities Act.

Standby Equity Distribution Agreement

Pursuant to our Standby Equity Distribution Agreement ("SEDA") dated July 15, 2005, we sold 9,861,933 shares of common stock to Cornell Capital on February 8, 2006. In accordance with the SEDA, the number of shares was calculated as $500,000 divided by $0.0507. We selected $500,000 as the gross advance for this particular SEDA transaction. The $0.0507 price per share was calculated, under the SEDA, by multiplying the lowest daily volume weighted average price (as quoted by Bloomberg L.P.) in the five-day trading period from February 1, 2006 to February 7, 2006 by 97%. From the indicated $500,000 gross advance, we actually received cash proceeds of $474,500 net of a 5% retainage fee and a $500 structuring fee.

We have stated in a SEC registration statement that the 3% discount and the 5% retainage fee constitute underwriting discounts, as does the $515,000 commitment fee (paid in the form of 725,353 shares of our common stock) which we paid to Cornell Capital in respect of the entire $15,000,000 SEDA commitment on July 15, 2005. The 9,861,933 shares were issued to Cornell Capital pursuant to the Securities Act Section 4(2) registration exemption.






Item 8.01 Other Events.

Effective February 15, 2006 we are engaging American Stock Transfer & Trust Company to be the transfer agent for our common stock, Class B Warrants, and any other securities registered under the Securities Exchange Act.









--------------------------------------------------------------------------------

Top of the Form
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


The Immune Response Corporation

February 14, 2006 By: /s/ Michael K. Green


--------------------------------------------------------------------------------

Name: Michael K. Green
Title: Chief Operating Officer & Chief Financial Officer

[spontanix]

bin mal gespannt was die forschungen an neurovax bringen,
selbst in deutschen ms-betroffenen foren wird davon geredet und die hoffnung daran ist groß.
was ich im net so über den studienverlauf lese scheints ja fortschritte zu machen

[can2]

Börse
NASDAQ OTC BB

Aktuell
0,12 USD

Zeit
16.02.06 21:40

Diff. Vortag
+25,00 %

Tages-Vol.
198.719,95

Gehandelte Stück
1,9 Mio.

[can2]

@spontanix

haste einen link für mich,wg. der deutschen ms-betroffenen foren-geschichte? kenne auch jemanden, der davon betroffen ist...

lg

wann sehen wir die 20cent?

[can2]

Börse
Frankfurt

Aktuell
0,11 EUR

Zeit
17.02.06 16:34

Diff. Vortag
+22,22 %

Tages-Vol.
3.242,93

Gehandelte Stück
31.524

Geld
0,09

Brief
0,12

Zeit
17.02.06 16:34

Spread
--

Geld Stk.
36.000

Brief Stk.
60.000

[Datek21]

RT in USA 0.16 Dollar....geht ab wie schmitz katze

[oski]

ich will den $

[can2]

@oski: dein 1usd wirste vielleicht ja bald sehen, wer weiß wie schnell es bald rauf geht, am anfang ist der herdentrieb langsam und unauffällig, sobald die leute es geschnallt haben, springen sie wie die bekloppten hinterher. das wird alles dynamischer...man darf nicht vergessen, das ein investor gute 10% der aktien kaufen will, des weiteren hat die us regierung glaube ich etwa 6 mio usd investiert...mediakamente phase2...warrant-geschichte bei 30-36cent? also wäre der aktienkurs um ein vielfaches höher, wenn das stimmt oder? die machen das gleich spiel wie bei calypte bio oder biocurex damals. biocurex ging von 0,03 auf 1,90 usd etwa?

Börse
NASDAQ OTC BB

Aktuell
0,16 USD

Zeit
23.02.06 21:59

Diff. Vortag
+40,35 %

Tages-Vol.
644.547,22

Gehandelte Stück
4,5 Mio.

Geld
0,158

Brief
0,16

Zeit
23.02.06 21:59

Spread
1,25%

Geld Stk.
5.000

Brief Stk.
5.000

[can2]

was sagt ihr zu diesen daten?


guckste hier:

Einzelteil-Eintragung 1.01 in eine materielle endgültige Vereinbarung. An Februar 8, 2006, die wir in eintrugen und einen Anmerkung Austausch-Vertrag schlossen und eine Anmerkung Neuausgabe Vereinbarung mit Cheshire verbindet LLC ("Cheshire"), das ein Teilnehmer unseres Direktor und Major Aktionärs Kevin Kimberlin ist. Diese Vereinbarungen betrafen eine gesicherte umwandelbare Anmerkung, die vorher von uns herausgegeben wurde und durch Cheshire, mit einer Hauptbalance gehalten war (vor den Vereinbarungen) von $5.740.928 (der "gesicherte Schuldschein"). Unter der Anmerkung Austausch-Vereinbarung gaben wir 53.425.204 Anteile neu-herausgegebene Stammaktien zu Cheshire gegen $1.005.683.31 der Direktion und $62.820.77 von anfallendem Interesse auf dem gesicherten Schuldschein heraus. Diese Verhandlung ergab antidilution Justagen unter den Bezeichnungen von einigen unserer hervorragenden abgeleiteten Aktien. Vornehmlich, resultierend aus "Schaltklinke" antidilution in der gesicherten Wandelschuldverschreibung und in den Stammaktienoptionsscheinen, die durch Cornell Hauptpartner gehalten wurden, Langspielplatte Bestimmungen ("Cornell Kapital"), den Konvertierungskurs und Übung Preis jener Aktien wurden bis $0.02 pro Anteil verringert. Infolgedessen wurde die hervorragende Hauptbalance $500.000 des Schuldscheins, der vorher in 791.765 Anteile Stammaktien (bei $0.6315 pro Anteil) umwandelbar gewesen war, in 25.000.000 Anteile Stammaktien umwandelbar; und die Ermächtigungen, die vorher für 500.000 Anteile exercisable gewesen
waren, wurden für 23.100.000 Anteile Stammaktien exercisable. Wir haben nicht mehr genügende autorisierten aber unissued, Anteile von Stammaktien, zum der Umwandlung oder der Übung der Sicherheiten des Cornell Kapitals für diese erweiterten Zahlen der Anteile von Stammaktien zu ermöglichen. In der Tat erforderte die Anmerkung Austausch-Vereinbarung Austeilung die Anteilreserven sogar eindringen, die vorher hergestellt worden waren, um die meisten unseren abgeleiteten Aktien zugrunde zu liegen, anders als vorhergehend-hergestellten Anteil des Cornell Kapitals aufhebt. Unter der Anmerkung Neuausgabe Vereinbarung war der Fälligkeitstermin des gesicherten Schuldscheines von einem Mai 31, 2007 bis Januar 1, 2009 ausgedehnt und in der Betrachtung für diese Verlängerung verringerten wir den Konvertierungskurs der restlichen Menge mit $4.735.244.69 Direktionen des gesicherten Schuldscheines bis $0.02 pro Anteil von Stammaktien. Anfallendes Interesse auf dem gesicherten Schuldschein ist auch bei $0.02 pro Anteil von Stammaktien umwandelbar. Vor der Anmerkung Austausch-Vereinbarung war der

Konvertierungskurs des gesicherten Schuldscheines $0.70 pro Anteil gewesen. Der Unterschied zwischen Umwandlung von $4.735.244.69 bei $0.70 pro Anteil und Umwandlung von

$4.735.244.69 bei $0.02 pro Anteil ist 229.997.599 zusätzliche Anteile Stammaktien. Wir haben nicht mehr genügende autorisierten aber unissued, Anteile von Stammaktien, zum der Umwandlung des gesicherten Schuldscheines in diese erweiterte Zahl der Anteile von Stammaktien zu ermöglichen. An Februar 9, 2006, nahmen wir an teil und führten eine Sicherheiten Kaufvereinbarung mit Qubit Holdings, LLC durch ("Qubit"). Gegen Bargeld $250.000 gaben trugen wir zu Qubit eine versprechende Anmerkung $250.000 heraus, gesichert durch im wesentlichen alle unsere Werte und pro Jahr Interesse bei 8% und reiften auf Januar 1, 2008 und Kabriolett in unsere Stammaktien bei $0.02 pro Anteil, plus 37.500.000 kurzfristige Ermächtigungen, um unsere Stammaktien bei $0.02 pro Anteil zu kaufen. In der Sicherheiten Kaufvereinbarung bewilligte Qubit uns das Recht, bis August 8 auch, 2006, gesetzt zu Qubit eine anderen sicherten $250.000 umwandelbare Anmerkung von wiebeschaffenheit und andere 37.500.000 kurzfristige Ermächtigungen von wiebeschaffenheit und ein anderes Bargeld $250.000 darauf zu empfangen. Wir haben nicht mehr genügende autorisierten aber unissued, Anteile von Stammaktien, zum der Umwandlung oder der Übung der abgeleiteten Aktien zu ermöglichen, die geherausgeben werden oder zu Qubit ausgabefähig. Zusätzlich zu den Aktien, die hierin beschrieben wurden, besaß Cheshire, vor diesen Verhandlungen, 13.689.838 Anteile unserer Stammaktien und exercisable Aktien für andere 19.923.548 Anteile unserer Stammaktien. Zusätzlich besaß Herr Kimberlin und seine Teilnehmer, vor diesen Verhandlungen, andere 896.614 Anteile unserer Stammaktien und abgeleitete Aktien andere 1.424.009 Anteile unserer Stammaktien überlagernd. Aufgrund der Verhandlungen, die oben beschrieben wurden, wurden neun hervorragende Ermächtigungen, die durch Cheshire besessen wurden, das durch ihre Bezeichnungen für eine Gesamtheit von 9.947.335 Anteilen Stammaktien zu einem gemischten Preis von $1.05 pro Anteil exercisable gewesen war, anstatt für eine Gesamtheit von 31.727.025 Anteilen Stammaktien zu einem gemischten Preis von $0.33 pro Anteil, über den Betrieb der Justagebestimmungen antidilution der Ermächtigungen belasten-durchschnittlichen exercisable. Keine der anderen abgeleiteten Aktien, die vom Herrn Kimberlin oder seins besessen werden, verknüpft erfuhr alle mögliche antidilution Justagen resultierend aus den Verhandlungen, die oben beschrieben werden. Qubit wird durch bestimmte Vertrauen besessen, die zugunsten der Kinder Herrn Kimberlins gebildet werden. Die Vertrauen sind und Qubit ist, gehandhabt durch einen unabhängigen Verwalter. Herr Kimberlin dementiert wirtschaftliches Eigentum aller Aktien, die von Qubit gehalten werden, weil Herr Kimberlin keine Energie hat zu wählen oder abzuschaffen, oder das Wählen oder die Einteilung, aller möglicher Aktien zu verweisen, die durch Qubit oder solche Vertrauen gehalten werden. An Februar 8, 2006, war der schließende Verkauf Preis unserer Stammaktien, wie durch das OTC Anschlagbrett berichtet $0.05 pro Anteil.

[EDDSON]

Hallo Leute!

Bin auch bei IMNR investiert und betrachte die Geschichte bis jetzt sehr positiv. Das Interesse in D steigt und immer mehr Leute kaufen IMNR. Charttechnisch sieht es wirklich sehr gut aus, "W" Formation wird heute beendet und wenn es nicht zu Gewinnmitnahmen am Abend kommen soll dann werden wir an obere Linie bleiben und vielleicht auch nächte Woche uns dort weiter bewegen.
Was sehr ungewönnlich an IMNR die letzte Woche zu beobachten war-Ausverkauf ist ausgeblieben!!! Es scheint wirklich zu funktionieren und viele glauben an die Geschichte und wollen am Anfang an dabei sein
Mein SK für heute 0,205-0,21$. Eine Kerze wird uns nur Shaden einrichten, da die sehr schnell verglühen wird und nur Zocker einlocken.

Also, viel Erfolg heute und STAY LONG


Gr ED

[can2]

hi eddson,

denke ähnlich, aber meistens gehts später doch sehr rasant rauf, sobald das publikum schnallt, was da abgeht. die erste zeit gehts noch stetig 2 rauf und einen wieder runter, die zeitintervalle verkürzen sich da der herdentrieb dann an ins rollen kommt. ich hoffe es geht erstmal so weiter wie bisher, dann kann ich mir bald mal meine wohnung neu einrichten, hust!

viel glück uns allen hier!

[can2]

Börse
NASDAQ OTC BB

Aktuell
0,16 USD

Zeit
27.02.06 16:14

Diff. Vortag
+10,34 %

Tages-Vol.
75.572,73

Gehandelte Stück
472.892

Geld
0,156

Brief
0,16

Zeit
27.02.06 15:42

Spread
2,5%

Geld Stk.
5.000

Brief Stk.
5.000

[can2]

geldkurs steigt, hop hop!

Börse
NASDAQ OTC BB

Aktuell
0,16 USD

Zeit
27.02.06 16:46

Diff. Vortag
+10,34 %

Tages-Vol.
106.487,99

Gehandelte Stück
669.233

Geld
0,159

Brief
0,16

[EDDSON]

Gruß an alle!

Es läuft wieder Grund:
http://www.stockhouse.com/news/news.asp?newsid=3464598&tick=…

Hoffe es geht weiter so

Gr ED

[can2]

Börse
NASDAQ OTC BB

Aktuell
0,1611 USD

Zeit
06.03.06 21:59

Diff. Vortag
+28,88 %

Tages-Vol.
448.206,95

Gehandelte Stück
3,1 Mio.

Geld
0,16

Brief
0,161

Zeit
06.03.06 22:02

Spread
0,621%

Geld Stk.
5.000

Brief Stk.
--

Schluss Vortag
0,125

Eröffnung
0,126

Hoch
0,169

Tief
0,125

52W Hoch
--

52W Tief
--

Split
--

[can2]

denkt an biocurex:von 0,02 auf 1,90 usd? nur geldkurs wieder!
Börse
NASDAQ OTC BB

Aktuell
0,24 USD

Zeit
07.03.06 22:00

Diff. Vortag
+48,98 %

Tages-Vol.
2,47 Mio.

Gehandelte Stück
13 Mio.

Geld
0,236

Brief
0,24

Zeit
07.03.06 21:50

Spread
1,667%

Geld Stk.
5.000

Brief Stk.
--

The Immune Response Corporation (OTCBB: IMNR) a biopharmaceutical company, engages in the development of immune-based therapy (IBT) in HIV and multiple sclerosis (MS). The company`s HIV products are based on its patented whole-killed virus technology, to stimulate HIV immune responses. It has three IBT programs under development: Remune, IR103, and NeuroVax. Remune, which is in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. IR103, which is in Phase I/II clinical trials, is an IBT for the treatment of HIV. IR103 incorporates an immunostimulatory oligonucleotide adjuvant. NeuroVax, which is in Phase II clinical trials, is an IBT for MS. The Immune Response Corporation was founded by Jonas Salk in 1986 and is headquartered in Carlsbad, California. With 66.19 million shares outstanding and an undisclosed short position, there is no longer a failure to deliver in shares of IMNR.

[LuckyLunatic]

Nachbörsliche News:

March 7, 2006

The Immune Response Corporation Completes $8 Million Financing

Carlsbad, California – March 7, 2006 – The Immune Response Corporation (OTCBB: IMNR.OB) announced today that it has completed a private placement of $8.0 million of secured notes which are convertible into 400,000,000 shares of common stock at $0.02 per share. The secured convertible notes accrue interest at 8% per year and mature on January 1, 2008. Investors also received warrants to purchase an aggregate of 1,200,000,000 shares of common stock at $0.02 per share which have the potential to generate an additional $24 million in gross proceeds. The first tranche of these warrants (600,000,000) expires the later of May 31, 2006, or 45 days following the registration of the shares underlying the warrants. The second tranche of these warrants (600,000,000) become exercisable 70 days after the expiration of the first tranche of the warrants and expire 45 days after they become exercisable. None of these derivative securities will be able to be converted into or exercised for common stock until the Company obtains stockholder approval to significantly increase its authorized number of shares of common stock.

“This offering puts us in a much stronger financial position, giving us immediate capital to pursue our business and clinical strategy,” said Michael K. Green, Chief Operating Officer and Chief Financial Officer. “More importantly, the $24 million potential additional proceeds from the two tranches of warrant exercises during 2006 could provide us with long-term capital to complete important phase II clinical trials over the next two years.”

Proceeds from the financing will be used to fund the Company’s ongoing and planned clinical activities and for general corporate purposes. Spencer Trask Ventures, Inc., an affiliated entity of two of the Company’s directors, served as the exclusive placement agent for the transaction.

[can2]

bin mal gespannt!

[can2]

pfuiiii, gewinnmitnahmen ganz dolle!

[EDDSON]

LAST NEWS

http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1313

[Monschinas]

Moin Leutz....bin auch mit dabei

[can2]

viel glück uns allen!

[can2]

also hört sich nicht so an, als würde man mit neuen aktien den kurs verwässern wollen oder was meint ihr?

Keine dieser abgeleiteten AktienSIND in der Lage, in umgewandelt zu werden oder für Stammaktien trainiert zu werden, bis die Firma Aktionärzustimmung erreicht, um seine autorisierte Zahl der Anteile von Stammaktien erheblich zu erhöhen. "anbietendes dieses setzt uns in eine viel stärkere Finanzlage ein und gibt uns sofortig Kapital, um unser Geschäft und klinische Strategie auszuüben,", sagte Michael K. Green, funktionierender Hauptoffizier und Finanzleiter. "wichtiger, konnten die möglichen zusätzlichen Erträge $24 Million von den zwei Scheibeen der Ermächtigung Übungen während 2006 uns mit langfristigem Kapital komplettes wichtiges Phase II zu den klinischen Versuchen über den folgenden zwei Jahren versehen."

[EDDSON]

Binn gespannt was wird aus IMNR??? Viele haben es schon abgeschrieben, zu Recht? Gestern waren mehrere große Käufe 50/80/100K Blocks und die Krönung-500K After Hours Insider decken sich und ich hoffe das wir bald ein Ausbruch zu alte Höhen erleben werden. GOOD TRADE

GR ED

[can2]

da kommt noch mehr!

[can2]

wird wohl noch dauern was?

[EDDSON]

Die Unsicherheit ist da und gestrige Teilausfünrungsverkäufe haben den Kurs schon richtig runter gedrückt. Von andere Seite manche haben die Zeit genutzt und billig eingekauft Am Ende(Afterhours) war wieder ein 500K Block da zu 0,1248 Ich persönlich denke dass wir jetzt auf 0,11$ abrutchen werden Wichtig sind NEWS!!! Wenn IMNR etwas festes rausbringt zb ein Regierungsauftrag oder Zulassung dann steigt Kurs wieder rapid hoch und die Anleger kriegen wieder Vertrauen. Also, abwarten

Gr ED

[can2]

ich halte meine stücke! hatte damals calypte zu früh verkauft, alle dachten, da kommt nix mehr und einge zeit später ging das teil von etwa 10cent auf 1,7 oder so ähnlich...schauen wir mal, die wirtschaft zieht an, siehe leitzinsen!

[can2]

Press Room
NaviSite Reports Second Quarter Fiscal Year 2006 Results
Sequential Revenue Growth of 3.4% over Q1 FY06
Tenth Consecutive Quarter of Positive EBITDA
Continued Strong Customer Bookings
Andover, Mass. March 13, 2006 - NaviSite, Inc. (Nasdaq: NAVI), a leading provider of IT hosting, outsourcing and professional services for mid- to large-sized organizations, today reported financial results for its second quarter of fiscal year 2006, which ended January 31, 2006.

Revenue for the second quarter of fiscal year 2006 was $26.3 million, compared to $25.4 million for the first quarter of fiscal year 2006 and $28.4 million for the second quarter of fiscal year 2005. Revenue for the second quarter of fiscal year 2005 included approximately $1.1 million from the Microsoft Business Solutions Software and Professional Services Practice, which was sold in July 2005. Revenue for the second quarter of fiscal year 2006 increased approximately $0.9 million, or 3.4%, over the first quarter of fiscal year 2006.

NaviSite recorded $2.9 million of EBITDA, excluding impairment, stock-based compensation and other one-time charges for the second quarter of fiscal year 2006, marking the Company’s tenth consecutive quarter of positive EBITDA. Excluding non-cash, stock-based compensation expense of $244,000, NaviSite generated gross profit of $7.9 million, or 30% of revenue, for the second quarter of fiscal year 2006, as compared to $7.7 million, or 27% of revenue, for the same fiscal quarter of 2005 and $8.0 million, or 31% of revenue, for the first quarter of fiscal year 2006. NaviSite recorded a net loss of $4.0 million, or a loss of $.14 cents per share, for the second quarter of fiscal year 2006, as compared to a loss of $4.6 million, or a loss of $.17 cents per share, for the same fiscal quarter of 2005.

The Company’s cash balance at the end of the second quarter of fiscal year 2006 was $1.9 million, an increase of $0.1 million from the end of the first quarter of fiscal year 2006. NaviSite had positive cash flow from operations of approximately $2.0 million in the second quarter of fiscal year 2006, which was substantially offset by cash flows from investing and financing activities. NaviSite has generated positive cash from operations in four of its last five fiscal quarters.

“We’re very pleased with our second consecutive quarter of organic revenue growth and our tenth consecutive quarter of positive EBITDA,” said Arthur Becker, CEO, NaviSite. “Our continued strong customer bookings speak to the value we’re delivering to our customers as their trusted partner of choice for hosting, outsourcing and professional services. We expect to continue our strong momentum moving into the second half of the year to make 2006 a year of solid growth for NaviSite.”

“We’re continuing to work with an investment banker engaged in the first quarter to facilitate the refinancing of the Company’s short-term debt associated with our Silicon Valley Bank credit facility and obligations arising from our acquisition of the AppliedTheory and Surebridge businesses,” said John Gavin, CFO, NaviSite. “The Company expects to close on this refinancing in the next 45 days.”

Business highlights for the second quarter of fiscal year 2006 include:

Increased hosting bookings by 63% over the second quarter of fiscal year 2005. Booked approximately $570,000 of new monthly recurring revenue with $13.4 million of total contract value, compared to approximately $350,000 of new monthly recurring revenue and $10.9 million of total contract value in the second quarter of fiscal year 2005.
Increased professional services bookings by 221% over the second quarter of fiscal year 2005. Closed approximately $3.2 million of professional services contract value, compared to approximately $1.0 million of professional services contract value in the second quarter of fiscal year 2005.
Signed 50 new customers in the second quarter of 2006, including four from NaviSite’s UK office. Deals closed in the second quarter included Coverpoint.biz, Performancing, LLC (formerly Text Link Ads, Inc.), Archimedes, Singlefin, Telstra, Ramsell Corporation and United Utilities.
Renewed existing customer contracts or expanded business with New York State Department of Labor, Premiere Global Services, Welch Allyn, DMSi, Quixote, SHOP.com and Lifespan.
Continued to reduce customer churn, defined as the loss of a customer or a reduction in a customer’s monthly revenue run rate, excluding our major accounts, at 0.9% per month for the quarter, compared to 2.1% per month for the second quarter of fiscal year 2005 and well below our goal of 2% per month. Churn for the first quarter of fiscal year 2006 was 1.0% per month.
Marked the one-year anniversary of our India operation by accomplishing several major milestones:
Expanded our operations to 90 employees;
Transitioned a portion of NaviSite’s PeopleSoft hosting support to NaviSite India and completed the first successful PeopleSoft customer engagement in NaviSite India;
Grew the NaviSite India Professional Services and Outsourcing Services;
Implemented a global 24x7 support environment for NaviSite’s core infrastructure management activities - including messaging, network management, database administration and services management; and
Built skill sets in various infrastructure and application domains including Windows, Unix, Exchange, Domino, Network Engineering and Help Desk; Oracle E-Business Suite, PeopleSoft Enterprise, JD Edwards EnterpriseOne; eBusiness technologies including Microsoft .NET, Java/J2EE, and open source.
Completed SAS 70 Type II (Statement on Auditing Standards No. 70) Audit for the Company’s San Jose, California facility. NaviSite’s data center in Andover, Massachusetts completed its fourth successful SAS 70 Type II Audit, demonstrating the Company’s commitment to compliance standards.
Recognized by HostReview with the Best Managed Hosting Service Award in its January 2006 Top 10 Web Host Awards. The Best Managed Hosting Service is an award intended to mark the companies with the best performance in the last month. The criteria for the award includes: overall presence of the company and equipment procurement, provisioning and installation, and network monitoring and management capabilities.
Launched a number of new and expanded product offerings including:
Monitoring Services: Extended the Company’s extensive monitoring capabilities to customers whose servers are located outside of a NaviSite data center. NaviSite’s Remote Monitoring Services simplify the application and infrastructure monitoring and management process by providing a comprehensive view of IT systems through one interface: NaviView, NaviSite’s IT management portal.
Help Desk Services: Launched formalized Help Desk Support Services for enterprise applications and desktop computers. NaviSite’s Application Help Desk Support Services provide front-line support for application-related questions regarding Oracle E-Business Suite, PeopleSoft and Siebel. NaviSite’s product offering for desktop support includes full end-user support, such as account management (e.g. account creation, resetting passwords, permission changes), PC troubleshooting, remote network management, VPN troubleshooting, DNS & WINS management, and dial-up troubleshooting.
Consulting Services for Business Intelligence: NaviSite Professional Services (NPS) launched a new set of solutions and services in Business Intelligence (BI) and Data Warehousing. Companies can turn to NaviSite to help define their Business Intelligence vision, build a Business Intelligence implementation roadmap and design Business Intelligence programs that effectively align a company’s strategic goals and priorities with its operations.
Guidance:
NaviSite projects revenue for the third quarter of fiscal year 2006 to be between $28.1 and $28.5 million, expected growth of 8% over the second quarter of fiscal year 2006, and projects revenue for fiscal year 2006 to be between $111.0 and $113.0 million. EBITDA, excluding impairment, stock-based compensation and one-time charges, is projected to be between $4.2 and $4.6 million for the third quarter of fiscal year 2006 and between $16.0 and $16.5 million for fiscal year 2006.

Conference Call Scheduled for March 14, 2006
NaviSite’s Chief Executive Officer, Arthur Becker, and Chief Financial Officer, John J. Gavin, Jr., will host a conference call to discuss NaviSite`s second quarter fiscal year 2006 financial results at 9:00 a.m. Eastern Time on March 14, 2006.

Call In Details:
Date and Time: Tuesday, March 14, 2006, 9:00 a.m. Eastern Time
Call In #: 866-383-7998 (International: 617-597-5329)
Enter PIN#: 31812739
Dial In Replay: 888-286-8010 (International: 617-801-6888)
Enter PIN #: 64461988
Available 30 minutes following the conclusion of the call and archived through March 14, 2007.
Archived Replay: http://www.navisite.com/earningscalls
Available 24 hours following conclusion of the call.
Call-in and replay details can also be found on NaviSite`s website at http://www.navisite.com/sublevel.aspx?id=112.

EBITDA
EBITDA is not a recognized measure for financial statement presentation under United States generally accepted accounting principles (U.S. GAAP). The Company believes that the non-GAAP measure of EBITDA provides investors with a useful supplemental measure of the Company`s actual and expected operating and financial performance by excluding the impact of interest, taxes, depreciation and amortization. The Company also excludes impairment, non-cash stock-based compensation and other one-time charges from its non-GAAP measure, as such items may be considered to be of a non-operational nature. EBITDA does not have any standardized definition and therefore may not be comparable to similar measures presented by other reporting companies. Management uses EBITDA to assist in evaluating the Company`s actual and expected operating and financial performance. These non-GAAP results should not be evaluated in isolation of, or as a substitute for, the Company`s financial results prepared in accordance with U.S. GAAP. A table reconciling the Company`s net loss, as reported, to EBITDA is included in the consolidated financial statements in this release. The Company believes that using expected EBITDA as a performance measure, together with expected net loss, will help investors better understand the Company`s underlying financial performance. A table reconciling expected net loss to expected EBITDA for the second quarter of fiscal year 2006 is also included in this release.

CLICK HERE TO VIEW THE FINANCIAL TABLES.


About NaviSite
NaviSite provides IT hosting, outsourcing and professional services for mid- to large-sized organizations. Leveraging a proven set of technologies and extensive subject matter expertise, we deliver cost-effective, flexible solutions that provide responsive and predictable levels of service for our clients’ businesses. Over 900 companies across a variety of industries rely on NaviSite to build, implement and manage their mission-critical systems and applications. NaviSite is a trusted advisor committed to ensuring the long-term success of our customers’ business applications and technology strategies. NaviSite has 14 state-of-the-art data centers and eight major office locations across the U.S., U.K. and India. For more information, please visit www.navisite.com.

###

This release contains forward-looking statements, which address a variety of subjects including the expected future operating and financial results, including profitability, revenue growth and EBITDA, the expected refinancing of the company’s indebtedness, success and performance of NaviSite`s product and service offerings, NaviSite`s strategic business plans for growing its customer base and increasing sales, the expected benefits, efficiencies, synergies and integration efforts of the Surebridge acquisition, and the expected financial results and growth of the combined entity. All statements other than statements of historical fact, including without limitation those with respect to NaviSite`s goals, plans and strategies set forth herein, are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: NaviSite`s success, including its ability to improve its gross profit, improve its cash flows, expand its operations and revenue, and reach and sustain profitability, depends on its ability to execute on its business strategy and the continued and increased demand for and market acceptance of its products and services; the possibility that financial forecasts of the Company may not be achieved, including those as to expected EBITDA and revenue, due to problems or unexpected costs that may arise in successfully integrating the Surebridge business or an inability to realize expected synergies or make expected future investments in the combined businesses NaviSite may be unable to raise the necessary funds to meet its payment obligations to certain creditors; NaviSite`s management may face strain on managerial and operational resources as they try to oversee the expanded operations; NaviSite may not be able to expand its operations in accordance with its business strategy; NaviSite may experience difficulties integrating technologies, operations and personnel in accordance with its business strategy; NaviSite`s acquisition of companies and businesses may not produce expected cost savings, operational efficiencies or revenue; NaviSite`s products, technologies, and resources may not successfully operate with the technology, resources and/or applications of third parties; NaviSite derives a significant portion of its revenue from a small number of customers and the loss of any of those customers would significantly damage NaviSite`s financial condition and results of operations; and increased competition and technological changes in the markets in which NaviSite`s competes. For a detailed discussion of cautionary statements that may affect NaviSite`s future results of operations and financial results, please refer to NaviSite`s filings with the Securities and Exchange Commission, including NaviSite`s most recent Quarterly Report on Form 10-Q. Forward-looking statements represent management`s current expectations and are inherently uncertain. We do not undertake any obligation to update forward-looking statements made by us. All logos, company and product names may be trademarks or registered trademarks of their respective owners.

[can2]

verkaufsdruck bzw gewinnmitnahmen lassen nach und nur noch stücke im Geld?

Börse
NASDAQ OTC BB

Aktuell
0,115 USD

Zeit
21.03.06 15:39

Diff. Vortag
-0,86 %

Tages-Vol.
3.960,75

Gehandelte Stück
34.250

Geld
0,115

Brief
--

Zeit
--

Spread
--

Geld Stk.
5.000

Brief Stk.
--

[pobeda]

Hallo,
kennt vieleicht einer die Gründe, wieso die Aktie so runtergeprügelt wurde?
Salute pobeda

[luckier]

wollte auch noch einsteigen aber,


The Immune Response Corporation Announces $4.1 Million Already Received from Exercise of Warrants from March 2006 Private Placement Financing: Resale Registration Statement is Declared Effective by the Securities and Exchange Commission
The Immune Response Corporation (OTCBB:IMNR) announced that its Registration Statement for the resale of common stock underlying the convertible notes and warrants issued in the Company's March 2006 private placement financing was declared effective today by the Securities and Exchange Commission. In that private placement, the Company issued $8.0 million of secured notes which are convertible into 400,000,000 shares of common stock at $0.02 per share. The secured convertible notes accrue interest at 8% per year and mature on January 1, 2008. Investors also received warrants to purchase an aggregate of 1,200,000,000 shares of common stock at $0.02 per share; these warrants, if fully exercised, would generate an additional $24 million in gross proceeds for the Company. The warrants are divided into two 600,000,000 warrant tranches.

Investors have in fact already exercised 205,000,000 warrants to generate $4.1 million of the potential $12 million in gross proceeds from the first tranche. The remaining 395,000,000 warrants of this first tranche expire 45 days following notification to the warrant holders of today's resale registration of the shares underlying the warrants. The second tranche of warrants (600,000,000) becomes exercisable 70 days after the expiration of the first tranche of the warrants and expires 45 days after they become exercisable.

"We are pleased that so many investors exercised their warrants even before the SEC declared the registration statement effective," said Michael K. Green, Chief Operating Officer and Chief Financial Officer. "This additional capital will enable us to continue our progress with Phase II clinical trials for both our multiple sclerosis (MS) and HIV products. We are optimistic about receiving the full potential proceeds from our March financing now that the registration statement is effective."

In related news, David Hochman, a director of the Company and former Managing Director of Spencer Trask Ventures, Inc., the placement agent for the March 2006 private placement financing, has entered into an agreement to provide strategic and financial consulting services to more actively support the Company's continued pursuit of its new corporate and clinical strategy.

"David has played a critical role in developing our new strategy and helping us secure the necessary financing," said Dr. Joseph O'Neill, President and Chief Executive Officer. "Having more of his time and focus will help us continue to bring our plans to fruition."

About The Immune Response Corporation

The Immune Response Corporation (OTCBB:IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.

NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific, cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down-regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.

IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company's first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.

NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com for more information.

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing.

Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of its product candidates, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that its product candidates might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of its product candidates in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and subsequent filings on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

NeuroVax(TM)is a trademark of The Immune Response Corporation. REMUNE(R) is a registered trademark of The Immune Response Corporation.


Immune Response Corporation
Michael K. Green, 760-431-7080
[e-mail]
or
ROI Associates (Investor Contact)
Robert Giordano, 212-495-0201
[e-mail]



Source: Business Wire (June 13, 2006 - 6:30 PM EDT)

News by QuoteMedia
www.quotemedia.com

[oski]

schade das die firma neue shares braucht, aber die tests kosten viel geld
werde bald wieder einsteigen

[Mambo7]

IMNR is unchanged today. In the past 6 months, IMNR is in a trading range with an average daily volume of 8.06 million shares. It is a liquid penny stock, suitable for frequent trading. Recently it was turning down. Now Tradetrek thinks IMNR is excessively oversold. IMNR has a Market Beta of 0.16. Each 100 shares of IMNR has a Value-At-Risk (VAR) of $0.




http://www.tradetrek.com/LiveComment/default.asp?symbol=IMNR

[Mambo7]

The Immune Response Corporation Announces Initial HIV-1 Viral Antigen Yields Improved at Least Two-Fold Through New Manufacturi
The Immune Response Corporation (OTCBB:IMNR) announced today the development of a serum-free, chemically defined cell culture medium for the production of HIV-1 from HUT-78 cells, a human T-cell lymphoma cell line. A poster on the medium optimization process is being presented this week at the Vaccine Technology conference in Puerto Vallarta, Mexico. This conference is being held June 25th-30th, and is a biopharmaceutical development and manufacturing event with a special emphasis on HIV vaccine candidates and other global vaccines.

The development of this medium is an important step in the development of a vaccine utilizing whole-inactivated HIV to stimulate the human immune system against the virus. The Immune Response Corporation is currently evaluating this approach for a therapeutic vaccine in clinical trials of its second-generation HIV immunotherapy IR103. This technology will also be utilized toward the development of a preventive vaccine candidate.

The purpose of a therapeutic vaccine for HIV is to bolster the immune system to more effectively mount a sustained attack against HIV-infected cells. This may be accomplished by allowing the body to create and maintain a memory of the core proteins making up the virus by exposing it to an inactivated form of HIV that could not infect or destroy the immune cells. In order to create this vaccine candidate, cells chronically infected with the virus require growth and expansion in large quantities. The resulting whole virus contained in the clarified production medium is then inactivated and further purified through a scientifically robust and strictly regulated process.

The Company has collaborated with Irvine Scientific, a leading medical device/biotechnology company located in Santa Ana, CA, to develop a chemically defined, serum-free cell culture medium for the production process that eliminates all animal-derived components, improves viral yield, and is designed to provide consistently high cell growth through to full-scale production, while maintaining the performance of the final vaccine product as an immunological stimulant against HIV.

"The progress reported at this conference represents a significant advance for the Company," said Peter Lowry, Vice President of Manufacturing Operations at The Immune Response Corporation. "This new serum-free medium greatly enhances our ongoing efforts toward an efficient, economically viable, and reproducible manufacturing process that will allow us to produce safe and consistent whole-inactivated viral vaccines in large quantities." Through a process of screening and optimization, the Company demonstrated that the human T-cell lymphoma cell line HUT-78 (chronically infected with HIV-1) can be grown and reliably passaged in a chemically-defined cell culture medium, with cell densities exceeding two million cells/ml. In addition, initial HIV-1 viral antigen yields were improved at least two-fold over the serum supplemented medium originally used.

The Company believes that, in parallel with the continuation of the IR103 Phase II clinical program, this new medium represents a valuable step in the development of an economically sound and transferable manufacturing process for the vaccine in the future.

About IR103

More than 25 million people have died since human immunodeficiency virus (HIV) was first recognized in 1981 (source: UNAIDS, December 2005), and the new infection rate continues to grow at an alarming rate. Despite medical advances, the worldwide pandemic continues to claim more than 3.1 million lives each year (source: UNAIDS, December 2005). Additional safe and effective treatments are desperately needed for the estimated 40 million adults and children living with HIV as of 2005.

IR103 is a second-generation HIV immunotherapy based on the Company's patented, whole-inactivated virus technology, which was co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company's first-generation HIV product candidate. Preclinical research and recent clinical data show that IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. This product differs from currently available antiretroviral drug therapies since it is designed to stimulate an HIV-infected individual's immune system to fight the virus.

About The Immune Response Corporation

The Immune Response Corporation (OTCBB:IMNR) is an immuno-pharmaceutical Company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of multiple sclerosis (MS) and IR103 for the treatment of HIV infection.

Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.

NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of multiple sclerosis (MS).

NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.

IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company's first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.

NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.

This news release contains forward-looking statements.

Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.

[Heinerle2]

heute Empfehlung auf thestockster.com

Greetinxx Heinerle2

[oski]

Antwort auf Beitrag Nr.: 22.324.462 von Heinerle2 am 28.06.06 21:16:33

0.0285 plus 30%

[Courtier]

HOT STOCK ALERT! = IMNR
Immune Response Corp. Website
Ticker Symbol: IMNR.OB
Pick Price: 0.0222
Current Price: 0.026 +18%
Target Price: $0.35
52 week high: $0.85!!!!!!!!!!!!
Industry: Biotechnology
Recommendation: MEGA BONUS BUY!

[zielony]

Was geht hier ab

[zielony]

[zielony]

The Immune Response Corporation Announces Initial HIV-1 Viral Antigen Yields Improved at Least Two-Fold Through New Manufacturing Process; Medium Optimization Process Presented This Week at the Vaccine Technology Conference

[oski]

Antwort auf Beitrag Nr.: 22.325.263 von zielony am 28.06.06 21:49:47

mein gedanke ist und wahr das pfizer die sache nicht mit IMNR ernst nahm sonst hätten wir schon lange das mittel gegen AIDS
nur meine meinung

[zielony]

Open Gaps
Direction Date range
down Jun-14-2006 0.077 to 0.065
down Jun-09-2006 0.09 to 0.089

[zielony]

Recent CandleStick Analysis
Very Bullish
Date Candle
Jun-26-2006 Homing Pigeon

[zielony]

http://www.stockta.com/cgi-bin/candle.pl?cobrand=&symb=IMNR&…

[zielony]

[zielony]

Habe durch Zufall diese Aktie in einem Interview mit Warren Buffet entdeckt Schöne Kaufkurse, hat jemand mehr Infos ???

[zielony]

Last:0.0294

IMNR - IMMUNE RESPONSE CORP DEL

Change: +45.45%
High:0.03

Low:0.022

Volume:69,438,714

[zielony]

Fundamental Data Table
52 Week High 0.85
52 Week Low 0.01
EPS -0.3
P/E Ratio 0.00
Shares Outstanding 263,000,000
Market Cap 7,735,000
Beta 1.957

[zielony]

Kein Zock, aber ein super Investment

http://biz.yahoo.com/bw/060627/20060627005345.html?.v=1

[Poppholz]

bin auch mit 40.000 Stück eingestiegen. Mal sehen was die USA heute Nachmittag macht.

[Poppholz]

[zielony]

Antwort auf Beitrag Nr.: 22.333.847 von Poppholz am 29.06.06 10:39:06

[Poppholz]

ein aktuellerer Artikel:

Encouraging mid-phase data for Immune Response drug
28th June 2006
By Tom Neilson

Preliminary phase II study results of The Immune Response Corporation's second-generation HIV immunotherapy, IR103, have shown the drug to have enhanced immunomodulatory effects over Remune, the company's first-generation immunotherapy.

IR103 is a co-formulation of Remune and a novel synthetic toll-like receptor (TLR-9) agonist adjuvant, Amplivax. The company presented the results at the International Symposium on HIV & Emerging Infectious Diseases (ISHEID) in Toulon, France.

IR103 differs from currently available antiretroviral drug therapies in that it is an immune-based therapy designed to replenish and enhance key immune cells that have been destroyed by the virus, thus allowing stimulation of an HIV-infected individual's immune system to fight the virus.

"The early results for IR103 in this clinical study are encouraging," said lead investigator, Dr Andrea Gori, of the Department of Internal Medicine and Surgery at San Paolo Hospital, University of Milan. "We can now proceed to further investigate the potential advance that IR103 may provide through its unique ability to actively stimulate an HIV patient's immune system to fight the virus."

http://www.pharmaceutical-business-review.com/article_news.a…

[Poppholz]

da die Aktie vor 2 Monaten noch bei über 10 Euro stand ist hier alles möglich.



(alles wird gut)

[Poppholz]

Antwort auf Beitrag Nr.: 22.334.567 von Poppholz am 29.06.06 11:03:58

SORRY!

Sollte 0,10 Euro heißen

(echt keine Absicht gewesen)

[Poppholz]

der 2-Jahres-Chart:

[zielony]

1,2€ ist auch nicht schlecht.
Sollte die Phase II positiv durchlaufen (und nach neuesten Meldungen tut sie das auch) sind sogar 2€ möglich.

[Poppholz]

Antwort auf Beitrag Nr.: 22.335.009 von zielony am 29.06.06 11:20:13

Vielleicht habe ich heute mein neuestes Longinvestment gefunden.



Momentan wird recht gut zu 0,032 Euro in Frankfurt eingekauft:

[zielony]

Antwort auf Beitrag Nr.: 22.335.104 von Poppholz am 29.06.06 11:23:14

Gleich bin ich drin

[oski]

vorb. 0,0298

[buxte]

Symbol: IMNR

L2 Summary
Bid Level #MM's Size Ask Level #MM's Size
0.0297 3 150 0.0298 1 50
0.0294 2 100 0.0299 2 100
0.0200 2 100 0.0310 1 50
0.0124 1 50 0.0350 1 50

L2 Quote:
MM on Bid : 9

MM ID Bid Size Time
HILL 0.0297 50 09:09:05
UBSS 0.0297 50 09:12:56
MAXM 0.0297 50 09:13:49
ETRD 0.0294 50 08:35:07
MERI 0.0294 50 08:49:56
ABLE 0.0200 50 07:47:40
OLMP 0.0200 50 09:08:53
BEST 0.0124 50 07:56:22
RBCM 0.0100 50 07:45:55



MM on Ask : 9

MM ID Ask Size Time
OLMP 0.0298 50 09:08:53
UBSS 0.0299 50 09:12:56
MAXM 0.0299 50 09:13:49
ETRD 0.0310 50 08:35:07
ABLE 0.0350 50 07:47:40
HILL 0.0400 50 09:09:05
BEST 0.0425 50 07:56:22
MERI 0.0830 50 08:49:56
RBCM 0.1203 50 07:45:55




Buxte

[oski]

IncreMental Advantage Initiates Coverage of The Immune Response Corporation with Price Target of $0.09 Per Share, Accumulate Rating
Jul 24, 2006 9:25:00 AM
Copyright Business Wire 2006
CARLSBAD, Calif.--(BUSINESS WIRE)--July 24, 2006--

The Immune Response Corporation (OTCBB: IMNR) announced today that IncreMental Advantage, an equity research firm, has initiated coverage on the Company with an Accumulate rating, and a price target of $0.09 per share. The Immune Response Corporation's product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by IncreMental's highly experienced biotechnology analyst, Robert LeBoyer, who has more than 14 years of Wall Street experience.

IncreMental Advantage noted in the report that, "The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials."

"We believe the Company's clinical programs and valuation justify a market capitalization of $200 million to $225 million. If we divide market valuation by the total number of shares outstanding at this time (current), the valuation is $0.31 to $0.38 per share. Dividing market capitalization by fully diluted shares outstanding gives a valuation of $0.08 to $0.09 per share ... When the current stock price is compared with the potential from the company's products, its equity seems almost like a non-expiring option on the trials. We believe these factors make IMNR an undervalued stock," concluded LeBoyer in his report.

To Access IncreMental Advantage research report

IncreMental Advantage's research report on The Immune Response Corporation is available at: http://www.roiny.com/clients-irc-research.php.

For additional information, please email ROI Group Associates at [e-mail] or call Mike Dodge at 212-495-0744.

IncreMental Advantage is an equity research and think tank that publishes research on companies and breaking developments on issues ranging from advertising to water utilities. IncreMental's research is highly regarded among institutional and individual investors from all over the world. Their research and events are dedicated to helping senior executives and institutional investors achieve IncreMental Advantages in their fields of expertise.